Novel risk loci for COVID-19 hospitalization among

admixed American populations 2

- Silvia Diz-de Almeida, 1,2,135 Raquel Cruz, 1,2,135 Andre D. Luchessi, José M. Lorenzo-Salazar, 4 3
- Miguel López de Heredia. ² Inés Quintela. ⁵ Rafaela González-Montelongo. ⁴ Vivian N. Silbiger. ³ 4
- Marta Sevilla Porras, 2,6 Jair Antonio Tenorio Castaño, 2,6,7 Julian Nevado, 3,6,7 Jose María 5
- Aguado, ^{8,9,10,11} Carlos Aguilar, ¹² Sergio Aguilera-Albesa, ^{13,14} Virginia Almadana, ¹⁵ Berta Almoguera, ^{16,2} Nuria Alvarez, ¹⁷ Álvaro Andreu-Bernabeu, ^{18,10} Eunate Arana-Arri, ^{19,20} Celso 6
- 7
- Arango, 18,21,10 María J. Arranz, 22 Maria-Jesus Artiga, 23 Raúl C. Baptista-Rosas, 24,25,26 María 8
- Barreda- Sánchez, 27,28 Moncef Belhassen-Garcia, 29,30 Joao F. Bezerra, Marcos A.C. Bezerra, 22 9
- Lucía Boix-Palop,³³ María Brion,^{34,35} Ramón Brugada,^{36,37,35,38} Matilde Bustos,³⁹ Enrique J. 10
- Calderón, ^{39,40,41} Cristina Carbonell, ^{42,30} Luis Castano, ^{19,43,2,44,45} Jose E. Castelao, ⁴⁶ Rosa Conde-11
- Vicente, 47 M. Lourdes Cordero-Lorenzana, 48 Jose L. Cortes-Sanchez, 49,50, Marta Corton, 16,2 M. 12
- Teresa Darnaude, ⁵¹ Alba De Martino-Rodríguez, ^{52,53} Victor del Campo-Pérez, ⁵⁴ Aranzazu Diaz 13
- de Bustamante,⁵¹ Elena Domínguez-Garrido,⁵⁵ Rocío Eirós,⁵⁶ María Carmen Fariñas,^{57,58,59} 14
- María J. Fernandez-Nestosa 60 Uxía Fernández-Robelo, 61 Amanda Fernández-Rodríguez, 62,11 15
- Tania Fernández-Villa, 63,41 Manuela Gago-Domínguez, 5,64 Belén Gil-Fournier, 65 Javier Gómez-16
- Arrue, 52,53 Beatriz González Álvarez, 52,53 Fernan Gonzalez Bernaldo de Quirós, 66 Anna 17
- González-Neira, ¹⁷ Javier González-Peñas, ^{18,10,21} Juan F. Gutiérrez-Bautista, ⁶⁷ María José 18
- Herrero, ^{68,69} Antonio Herrero-Gonzalez, ⁷⁰ María A. Jimenez-Sousa, ^{62,11} María Claudia Lattig, ^{71,72} 19
- Anabel Liger Borja, 73 Rosario Lopez-Rodriguez, 16,2,74 Esther Mancebo, 75,76 Caridad Martín-20
- López, 73 Vicente Martín, 63 41 Oscar Martinez-Nieto, 77,72 Iciar Martinez-Lopez, 78,79 Michel F. 21
- Martinez-Resendez, 49 Ángel Martinez-Perez, 80 Juliana F. Mazzeu, 81,82,83 Eleuterio Merayo 22
- Macías,⁸⁴ Pablo Minguez,^{16,2} Victor Moreno Cuerda,^{85,86} Silviene F. Oliveira,^{87,88,83,89} Eva 23
- Ortega-Paino, ²³ Mara Parellada, ^{18,21,10} Estela Paz-Artal, ^{75,76,90} Ney P.C. Santos, ⁹¹ Patricia Pérez-24
- Matute, 92 Patricia Perez, 93 M. Elena Pérez-Tomás, 27 Teresa Perucho, 94 Mel·lina Pinsach-25
- Abuin, 36,35 Guillermo Pita, 17 Ericka N. Pompa-Mera, 95,96 Gloria L. Porras-Hurtado, 97 Aurora 26
- Pujol, 98,2,99 Soraya Ramiro León, 65 Salvador Resino, 62,11 Marianne R. Fernandes, 91,100 Emilio 27
- Rodríguez-Ruiz, 101,64 Fernando Rodriguez-Artalejo, 102,103,41,104 José A. Rodriguez-Garcia, 105 28
- Francisco Ruiz-Cabello, 67,106,107 Javier Ruiz-Hornillos, 108,109,110 Pablo Ryan, 111,112,113,11 José 29
- Manuel Soria, 80 Juan Carlos Souto, 114 Eduardo Tamayo, 115,116,11 Alvaro Tamayo-Velasco, 117 30
- Juan Carlos Taracido-Fernandez, Alejandro Teper, Lilian Torres-Tobar, Miguel 31
- Urioste, 120 Juan Valencia-Ramos, 121 Zuleima Yáñez, 122 Ruth Zarate, 123 Itziar de Rojas, 124,125 32
- Agustín Ruiz, 124,125 Pascual Sánchez, 126 Luis Miguel Real, 127 SCOURGE Cohort Group, Encarna 33
- Guillen-Navarro, ^{27,128,129,130} Carmen Ayuso, ^{16,2} Esteban Parra, ¹³¹ José A. Riancho, ^{57,58,59,2} 34
- Augusto Rojas-Martinez. 132 Carlos Flores. 4,133,134,136,* Pablo Lapunzina. 2,67,136 Ángel 35
- Carracedo. 1,2,5,64,136,** 36
- Affiliations 37
- 38 ¹, Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CIMUS),
- 39 Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 40 ², CIBERER, ISCIII, Madrid, Spain

- 41 ³, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
- 42 Toxicologicas, Natal, Brazil
- ⁴, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife,
- 44 Spain
- 45 ⁵, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
- 46 Santiago de Compostela, Spain
- 47 ⁶, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
- 48 IDIPAZ, Madrid, Spain
- 49 ⁷, ERN-ITHACA-European Reference Network
- 50 ⁸, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
- 51 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- ⁹, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
- 53 Salud Carlos III, Madrid, Spain
- 54 ¹⁰, School of Medicine, Universidad Complutense, Madrid, Spain
- 55 ¹¹, CIBERINFEC, ISCIII, Madrid, Spain
- 56 ¹², Hospital General Santa Bárbara de Soria, Soria, Spain
- 57 ¹³, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
- 58 Pamplona, Spain
- 59 ¹⁴, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 60 ¹⁵, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 61 ¹⁶, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
- 62 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 63 ¹⁷, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- 64 ¹⁸, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
- 65 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 66 ¹⁹, Biocruces Bizkai HRI, Bizkaia, Spain
- 67 ²⁰, Cruces University Hospital, Osakidetza, Bizkaia, Spain
- 68 ²¹, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
- 69 Carlos III, Madrid, Spain
- 70 ²², Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 71 ²³, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 72 ²⁴, Hospital General de Occidente, Zapopan Jalisco, Mexico
- 73 ²⁵, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá Jalisco, Mexico
- 74 ²⁶, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalaiara, Tonalá
- 75 idisJalisco, Mexico

- 76 ²⁷, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- 77 ²⁸, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- 78 ²⁹, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
- 79 Enfermedades Infecciosas, Salamanca, Spain
- 80 ³⁰, Universidad de Salamanca, Salamanca, Spain
- 81 ³¹, Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Brazil
- 82 ³², Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 83 ³³, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- 84 ³⁴, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
- 85 Compostela, Spain
- 86 ³⁵, CIBERCV, ISCIII, Madrid, Spain
- 87 ³⁶, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
- 88 Spain
- 89 ³⁷, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 90 ³⁸, Hospital Josep Trueta, Cardiology Service, Girona, Spain
- 91 ³⁹, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 92 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 93 ⁴⁰, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
- 94 Seville, Spain
- 95 ⁴¹, CIBERESP, ISCIII, Madrid, Spain
- 96 ⁴², Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
- 97 Spain
- 98 ⁴³, Osakidetza, Cruces University Hospital, Bizkaia, Spain
- 99 44, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
- 100 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 101 ⁴⁵, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- 102 ⁴⁶, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de
- 103 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 104 ⁴⁷, Hospital Universitario Río Hortega, Valladolid, Spain
- 105 ⁴⁸, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
- 106 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 107 ⁴⁹, Tecnológico de Monterrey, Monterrey, Mexico
- 108 ⁵⁰, Otto von Guericke University, Departament of Microgravity and Translational Regenerative
- 109 Medicine, Magdeburg, Germany
- 110 ⁵¹, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain

- 111 ⁵², Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 112 ⁵³, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- ⁵⁴, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia
- de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 115 ⁵⁵, Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 116 ⁵⁶, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 117 ⁵⁷, IDIVAL, Cantabria, Spain
- 118 ⁵⁸, Universidad de Cantabria, Cantabria, Spain
- 119 ⁵⁹, Hospital U M Valdecilla, Cantabria, Spain
- 120 ⁶⁰, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 121 ⁶¹, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
- 122 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 123 ⁶², Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
- de Salud Carlos III (ISCIII), Madrid, Spain
- 125 ⁶³, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) Instituto de
- 126 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 127 ⁶⁴, IDIS
- 128 ⁶⁵, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 129 ⁶⁶, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 130 ⁶⁷, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
- 131 Granada, Spain
- 132 ⁶⁸, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 133 ⁶⁹, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 134 ⁷⁰, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 135 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 136 ⁷¹, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
- 137 ⁷², SIGEN Alianza Universidad de los Andes Fundación Santa Fe de Bogotá, Bogotá,
- 138 Colombia
- 139 ⁷³, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 140 ⁷⁴, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización
- 141 Montepríncipe, 28660 Boadilla del Monte, España
- 142 ⁷⁵, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 143 ⁷⁶, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
- 144 Immunology and Immunodeficiencies Group, Madrid, Spain

- ⁷⁷, Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
- 146 ⁷⁸, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- 147 ⁷⁹, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
- 148 Islas Baleares, Spain
- 149 ⁸⁰, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
- 150 Pau, IIB Sant Pau, Barcelona, Spain
- 151 ⁸¹, Universidade de Brasília, Faculdade de Medicina, Brazil
- 152 ⁸², Programa de Pós-Graduação em Ciências Médicas (UnB), Brazil
- 153 ⁸³, Programa de Pós-Graduação em Ciencias da Saude (UnB), Brazil
- 154 ⁸⁴, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 155 ⁸⁵, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 156 ⁸⁶, Universidad Francisco de Vitoria, Madrid, Spain
- 157 ⁸⁷, Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
- 158 Brasília, Brazil
- 159 ⁸⁸, Programa de Pós-Graduação em Biologia Animal (UnB), Brazil
- 160 ⁸⁹, Programa de Pós-Graduação Profissional em Ensino de Biologia (UnB), Brazil
- 161 ⁹⁰, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and ENT,
- 162 Madrid, Spain
- ⁹¹, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
- 164 ⁹², Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
- 165 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 166 ⁹³, Inditex, A Coruña, Spain
- 167 ⁹⁴, GENYCA, Madrid, Spain
- 168 ⁹⁵, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
- de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 170 ⁹⁶. Instituto Mexicano del Seguro Social (IMSS). Centro Médico Nacional La Raza, Hospital de
- 171 Infectología, Mexico City, Mexico
- 172 ⁹⁷, Clinica Comfamiliar Risaralda, Pereira, Colombia
- 173 ⁹⁸, Bellyitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
- 174 L'Hospitalet de Llobregat, Spain
- 175 ⁹⁹, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 176 ¹⁰⁰, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 177 ¹⁰¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
- 178 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain

- 179 ¹⁰², Department of Preventive Medicine and Public Health, School of Medicine, Universidad
- 180 Autónoma de Madrid, Madrid, Spain
- 181 ¹⁰³, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain
- 182 ¹⁰⁴, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 183 ¹⁰⁵, Complejo Asistencial Universitario de León, León, Spain
- 184 ¹⁰⁶, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- 185 ¹⁰⁷, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
- 186 Granada, Spain
- 187 Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 188 109, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
- 189 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 190 ¹¹⁰, Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 191 ¹¹¹, Hospital Universitario Infanta Leonor, Madrid, Spain
- 192 ¹¹², Complutense University of Madrid, Madrid, Spain
- 193 ¹¹³, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- 194 114, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
- 195 Barcelona, Spain
- 196 ¹¹⁵, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,
- 197 Valladolid, Spain
- 198 ¹¹⁶, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- 199 117, Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,
- 200 Valladolid, Spain
- 201 ¹¹⁸, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 202 ¹¹⁹, Fundación Universitaria de Ciencias de la Salud
- 203 ¹²⁰, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 204 ¹²¹, University Hospital of Burgos, Burgos, Spain
- 205 ¹²², Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 206 ¹²³, Centro para el Desarrollo de la Investigación Científica, Paraguay
- 207 124 183, Research Center and Memory clinic, ACE Alzheimer Center Barcelona, Universitat
- 208 Internacional de Catalunya, Spain
- 209 125 184, Centre for Biomedical Network Research on Neurodegenerative Diseases (CIBERNED),
- 210 Instituto de Salud Carlos III, Madrid, Spain
- 211 126 185, CIEN Foundation/Queen Sofia Foundation Alzheimer Center, Madrid, Spain

- 212 127 186, Hospital Universitario de Valme, Unidad Clínica de Enfermedades Infecciosas y
- 213 Microbiología, Sevilla, Spain
- 214 ¹²⁸ 124, Sección Genética Médica Servicio de Pediatría, Hospital Clínico Universitario Virgen
- de la Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- 216 129 125, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
- 217 Universidad de Murcia (UMU), Murcia, Spain
- 218 ¹³⁰ ¹²⁶, Grupo Clínico Vinculado, Centre for Biomedical Network Research on Rare Diseases
- 219 (CIBERER), Instituto de Salud Carlos III, Madrid, Spain
- 220 ¹³¹ Department of Anthropology, University of Toronto at Mississauga, Mississauga, Ontario,
- 221 Canada.
- 222 ¹³², Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey,
- 223 Mexico

- 224 ¹³³ ¹²⁹, Research Unit, Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de
- 225 Tenerife, Spain
- 226 ¹³⁴ 130, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto
- 227 de Salud Carlos III, Madrid, Spain
- 228 ¹³⁵ 131, These authors contributed equally: Silvia Diz-de Almeida, Raquel Cruz
- 229 ^{136 132}, These authors contributed equally: Carlos Flores, Pablo Lapunzina, Ángel Carracedo
- *Correspondence: cflores@ull.edu.es
- **Correspondence: angel.carracedo@usc.es

Abstract

The genetic basis of severe COVID-19 has been thoroughly studied and many genetic risk factors shared between populations have been identified. However, reduced sample sizes from non-European groups have limited the discovery of population-specific common risk loci. In this second study nested in the SCOURGE consortium, we have conducted the largest GWAS meta-analysis for COVID-19 hospitalization in admixed Americans, comprising a total of 4,702 hospitalized cases recruited by SCOURGE and other seven participating studies in the COVID-19 Host Genetic Initiative. We identified four genome-wide significant associations, two of which constitute novel loci and first discovered in Latin-American populations (*BAZ2B* and *DDIAS*). A trans-ethnic meta-analysis revealed another novel cross-population risk locus in *CREBBP*. Finally, we assessed the performance of a cross-ancestry polygenic risk score in the SCOURGE admixed American cohort.

Introduction

To date, more than 50 loci associated to COVID-19 susceptibility, hospitalization, and severity have been identified using genome-wide association studies (GWAS)^{1,2}. The COVID-19 Host Genetics Initiative (HGI) has made significant efforts³ to augment the power to identify disease loci by recruiting individuals from diverse populations and conducting a trans-ancestry meta-analysis. Despite this, the lack of genetic diversity and a focus on cases of European ancestries still predominate in the studies^{4,5}. Besides, while trans-ancestry meta-analyses are a powerful approach for discovering shared genetic risk variants with similar effects across populations⁶, they may fail to identify risk variants that have larger effects on particular underrepresented populations. Genetic disease risk has been shaped by the particular evolutionary history of populations and the environmental exposures⁷. Their action is particularly important for infectious

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

diseases due to the selective constrains that are imposed by the host-pathogen interactions^{8,9}. Literature examples of this in COVID-19 severity includes a *DOCK*2 gene variant in East Asians¹⁰, and frequent loss of function variants in *IFNAR1* and IFNAR2 genes in Polynesian and Inuit populations, respectively 11,12. Including diverse populations in case-control GWAS studies with unrelated participants usually require a prior classification of individuals in genetically homogeneous groups, which are typically analysed separately to control the population stratification effects¹³. Populations with recent admixture impose an additional challenge to the GWAS due to their complex genetic diversity and linkage disequilibrium (LD) patterns, requiring the development of alternative approaches and a careful inspection of results to reduce the false positives due to population structure⁷. In fact, there are benefits in study power from modelling the admixed ancestries either locally, at regional scale in the chromosomes, or globally, across the genome, depending on factors such as the heterogeneity of the risk variant in frequencies or the effects among the ancestry strata¹⁴. Despite the development of novel methods specifically tailored for the analysis of admixed populations¹⁵, the lack of a standardized analysis framework and the difficulties to confidently cluster the admixed individuals into particular genetic groups often leads to their exclusion from GWAS. The Spanish Coalition to Unlock Research on Host Genetics on COVID-19 (SCOURGE) recruited COVID-19 patients between March and December 2020 from hospitals across Spain and from March 2020 to July 2021 in Latin-America (https://www.scourge-covid.org). A first GWAS of COVID-19 severity among Spanish patients of European descent revealed novel disease loci and explored age and sex varying effects of the genetic factors¹⁶. Here we present the findings of a GWAS metaanalysis in admixed American (AMR) populations, comprising individuals from the

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

SCOURGE Latin-American cohort and the HGI studies, which allowed to identify two novel severe COVID-19 loci, BAZ2B and DDIAS. Further analyses modelling the admixture from three genetic ancestral components and performing a trans-ethnic metaanalysis led to the identification of an additional risk locus near CREBBP. We finally assessed a cross-ancestry polygenic risk score model with variants associated with critical COVID-19. **Results** Meta-analysis of COVID-19 hospitalization in admixed Americans Study cohorts Within the SCOURGE consortium, we included 1,608 hospitalized cases and 1,887 controls (not hospitalized COVID-19 patients) from Latin-American countries and from recruitments of individuals of Latin-American descend conducted in Spain (Supplementary Table 1). Quality control details and estimation of global genetic inferred ancestry (GIA) (supplementary Figure 1) are described in Methods, whereas clinical and demographic characteristics of patients included in the analysis are shown in Table 1. Summary statistics from the SCOURGE cohort were obtained under a logistic mixed model with the SAIGE model (Methods). Another seven studies participating in the COVID-19 HGI consortium were included in the meta-analysis of COVID-19 hospitalization in admixed Americans (Figure 1). GWAS meta-analysis We performed a fixed-effects GWAS meta-analysis using the inverse of the variance as weights for the overlapping markers. The combined GWAS sample size consisted of 4,702 admixed AMR hospitalized cases and 68,573 controls.

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

This GWAS meta-analysis revealed genome-wide significant associations at four risk loci (Table 2, Figure 2), two of which (BAZ2B and DDIAS) were novel discoveries. Variants of these loci were prioritized by positional and expression quantitative trait loci (eQTL) mapping with FUMA, identifying four lead variants linked to other 310 variants and 31 genes (Supplementary Tables 2-4). A gene-based association test revealed a significant association in BAZ2B and in previously known COVID-19 risk loci: LZTFL1, XCR1, FYCO1, CCR9, and IFNAR2 (Supplementary Table 5). Located within the gene BAZ2B, the sentinel variant rs13003835 is an intronic variant associated with an increased risk of COVID-19 hospitalization (Odds Ratio [OR]=1.20, 95% Confidence Interval [CI]=1.12-1.27, p=3.66x10⁻⁸). This association was not previously reported in any GWAS of COVID-19 published to date. Interestingly, rs13003835 did not reach significance (p=0.972) in the COVID-19 HGI trans-ancestry meta-analysis including the five population groups¹. Based on our mapping strategy (see Methods), we also prioritized *PLA2R1*, *LY75*, *WDSUB1*, and *CD302* in this locus. The other novel risk locus is led by the sentinel variant rs77599934, a rare intronic variant located in chromosome 11 within DDIAS and associated with risk of COVID-19 hospitalization (OR=2.27, 95%CI=1.70-3.04, p=2.26x10⁻⁸). The *PRCP* gene was an additional prioritized gene at this locus. We also observed a suggestive association with rs2601183 in chromosome 15, which is located between ZNF774 and IQGAP1 (allele-G OR=1.20, 95%CI=1.12-1.29, p=6.11x10⁻⁸, see Supplementary Table 2), which has not yet been reported in any other GWAS of COVID-19 to date. This sentinel variant is in perfect LD $(r^2=1)$ with rs601183, an eQTL of ZNF774 in the lung.

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

The GWAS meta-analysis also pinpointed two significant variants at known loci, LZTFL1 and FOXP4. The SNP rs35731912 was previously associated with COVID-19 severity in EUR populations¹⁷, and it was mapped to LZTFL1. As for rs2477820, while it is a novel risk variant within gene FOXP4, it has a moderate LD $(r^2=0.295)$ with rs2496644, which has been linked to COVID-19 hospitalization¹⁸. This is consistent with the effects of LD in tag-SNPs when conducting GWAS in diverse populations. Functional mapping of novel risk variants Bayesian fine mapping We performed different approaches to narrow down the prioritized loci to a set of most probable genes driving the associations. First, we computed credible sets at the 95% confidence for causal variants and annotated them with VEP and the V2G aggregate scoring (Supplementary Table 6, Supplementary Figure 3). The 95% confidence credible set from the region of chromosome 2 around rs13003835 included 76 variants. However, the approach was unable to converge allocating variants in a 95% confidence credible set for the region in chromosome 11. Colocalization of eQTLs To determine if the novel genetic risk loci were associated with gene expression in relevant tissues (whole blood, lung, lymphocytes, and oesophagus mucosa), we computed the posterior probabilities (PP) of colocalization for overlapping variants allocated to the 95% confidence credible set. We used the GTEx v8 tissues as the main expression dataset, although it is important to consider that the eQTL associations were carried out mainly on individuals of EUR ancestries. To confirm the colocalization in other ancestries, we also performed analyses on three expression datasets computed on admixed AMR, leveraging data from individuals with high African GIA, high Native-

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

American ancestry, and from a pooled cohort (Methods). Results are shown in the supplementary Table 7. Five genes (LY75, BAZ2B, CD302, WDSUB1, and PLA2R1) were the candidates for eQTL colocalization in the associated region in chromosome 2. However, LY75 emerged as the most likely causal gene for this locus since the colocalization in whole blood was supported with a PP for H4 (PPH4) of 0.941 and with robust results (supplementary Figure 4). Moreover, this also allowed to prioritize rs12692550 as the most probable causal variant for both traits at this locus with a PP_SNP_H4 of 0.74. Colocalization with gene expression data from admixed AMR validated this finding. LY75 also had evidence of colocalization in lungs (PPH4=0.887) and the esophagus mucosa (PPH4=0.758). However, we could not prioritize a single causal variant in these two other tissues and sensitivity analyses revealed a weak support. CD302 and BAZ2B were the second and third most likely genes that could drive the association, respectively, according to the colocalization evidence. CD302 was the most probable according to the high AFR genetic ancestries dataset (supplementary Figure 5). Despite the chromosome 11 region failing to colocalize with gene expression associations for any of the tissues, the lead variant rs77599934 is in moderate-to-strong LD (r²=0.776) with rs60606421, which is an eQTL associated to a reduced expression of DDIAS in the lungs (supplementary Figure 6). The highest PPH4 for DDIAS was in the high AFR genetic ancestry expression dataset (0.71). *Transcriptome-wide association study (TWAS)* Five novel genes, namely SLC25A37, SMARCC1, CAMP, TYW3, and S100A12 (supplementary Table 8) were found significantly associated in the cross-tissue TWAS.

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

To our knowledge, these genes have not been reported previously in any COVID-19 TWAS or GWAS analyses published to date. In the single tissue analyses, ATP50 and CXCR6 were significantly associated in lungs, CCR9 was significantly associated in whole blood, and IFNAR2 and SLC25A37 were associated in lymphocytes. Likewise, we carried out the TWAS analyses using the models trained in the admixed populations. However, no significant gene-pairs were detected in this case. The 50 genes with the lowest p-values are shown in the supplementary Table 9. Genetic architecture of COVID-19 hospitalization in AMR populations Allele frequencies of rs13003835 and rs77599934 across ancestries Neither rs13003835 (BAZ2B) or rs77599934 (DDIAS) were significantly associated in the COVID-19 HGI B2 cross-population or population-specific meta-analyses. Thus, we investigated their allele frequencies (AF) across populations and compared their effect sizes. According to gnomAD v3.1.2, the T allele at rs13003835 (BAZ2B) has an AF of 43% in admixed AMR groups while AF is lower in the EUR populations (16%) and in the global sample (29%). Local ancestry inference (LAI) reported by gnomAD shows that within the Native-American component, the risk allele T is the major allele, whereas it is the minor allele within the African and European LAI components. These large differences in AF might be the reason underlying the association found in AMR populations. However, when comparing effect sizes between populations, we found that they were in opposite direction between SAS-AMR and EUR-AFR-EAS and that there was a large heterogeneity among them (Figure 3). rs77599934 (DDIAS) had an AF of 1.1% for the G allele in the non-hospitalized controls (Table 2), in line with the recorded gnomAD AF of 1% in admixed AMR

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

groups. This variant has potential to be population-specific variant, given the allele frequencies in other population groups such as EUR (0% in Finnish, 0.025% in non-Finnish), EAS (0%) and SAS (0.042%) and its greater effect size over AFR populations (Figure 3). Examining the LAI, the G allele occurs at 1.1% frequency in the African component while it is almost absent in the Native-American and European. Due to its low MAF, rs77599934 was not analyzed in the COVID-19 HGI B2 cross-population meta-analysis and was only present in the HGI B2 AFR population-specific metaanalysis, precluding the comparison (Figure 3). For this reason, we retrieved the variant with the lowest p-value within a 50 kb region around rs77599934 in the COVID-19 HGI cross-population analysis to investigate if it was in moderate-to-strong LD with our sentinel variant. The variant with the smallest p-value was rs75684040 (OR=1.07, 95%CI=1.03-1.12, p=1.84x10⁻³). Yet, LD calculations using the 1KGP phase 3 dataset indicated that rs77599934 and rs75684040 were poorly correlated (r^2 =0.11). *Cross-population meta-analyses* We carried out two cross-ancestry inverse variance-weighted fixed-effects metaanalyses with the admixed AMR GWAS meta-analysis results to evaluate whether the discovered risk loci replicated when considering other population groups. In doing so, we also identified novel cross-population COVID-19 hospitalization risk loci. First, we combined the SCOURGE Latin American GWAS results with the HGI B2 ALL analysis (supplementary Table 10). We refer to this analysis as the SC-HGI_{ALL} meta-analysis. Out of the 40 genome-wide significant loci associated with COVID-19 hospitalization in the last HGI release¹, this study replicated 39 and the association was stronger than in the original study in 29 of those (supplementary Table 11). However, the variant rs13003835 located in BAZ2B did not replicate (OR=1.00, 95%CI=0.98-1.03, p=0.644).

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

In this cross-ancestry meta-analysis, we replicated two associations that were not found in HGIv7 albeit they were sentinel variants in the latest GenOMICC meta-analysis². We found an association at the CASC20 locus led by the variant rs2876034 (OR=0.95, 95%CI=0.93-0.97, p=2.83x10⁻⁸). This variant is in strong LD with the sentinel variant of that study (rs2326788, r^2 =0.92), which was associated with critical COVID-19². Besides, this meta-analysis identified the variant rs66833742 near ZBTB7A associated with COVID-19 hospitalization (OR=0.94, 95%CI=0.92-0.96, p=2.50x10⁻⁸). Notably. rs66833742 or its perfect proxy rs67602344 ($r^2=1$) are also associated with upregulation of ZBTB7A in whole blood and in esophagus mucosa. This variant was previously associated with COVID-19 hospitalization². In a second analysis, we also explored the associations across the defined admixed AMR, EUR, and AFR ancestral sources by combining through meta-analysis the SCOURGE Latin American GWAS results with the HGI studies in EUR, AFR, and admixed AMR, and excluding those from EAS and SAS (Supplementary Table 12). We refer to this as the SC-HGI_{3POP} meta-analysis. The association at rs13003835 (BAZ2B, OR=1.01, 95%CI=0.98-1.03, p=0.605) was not replicated and rs77599934 near *DDIAS* could not be assessed, although the association at the ZBTB7A locus was confirmed $(rs66833742, OR=0.94, 95\%CI=0.92-0.96, p=1.89x10^{-8})$. The variant rs76564172 located near CREBBP also reached statistical significance (OR=1.31, 95% CI=1.25-1.38, p=9.64x10⁻⁹). The sentinel variant of the region linked to *CREBBP* (in the transancestry meta-analysis) was also subjected a Bayesian fine mapping (supplementary Table 6) and colocalization with eQTLs under the GTEx v8 MASHR models in lungs, esophagus mucosa, whole blood, and transformed lymphocytes. Eight variants were included in the credible set for the region in chromosome 16 (meta-analysis SC-HGI_{3POP}), although *CREBBP* did not colocalize in any of the tissues.

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

even in an admixed population.

Polygenic risk score models Using the 49 variants associated with disease severity that are shared across populations according to the HGIv7, we constructed a polygenic risk score (PGS) model to assess its generalizability in the admixed AMR (Supplementary Table 13). First, we calculated the PGS for the SCOURGE Latin Americans and explored the association with COVID-19 hospitalization under a logistic regression model. The PGS model was associated with a 1.48-fold increase in COVID-19 hospitalization risk per every PGS standard deviation. It also contributed to explain a slightly larger variance (R2=1.07%) than the baseline model. Subsequently, we divided the individuals into PGS deciles and percentiles to assess their risk stratification. The median percentile among controls was 40, while in cases it was 63. Those in the top PGS decile exhibited a 5.90-fold (95% CI=3.29-10.60, p=2.79x10⁻⁹) greater risk compared to individuals in the lowest decile, whereas the effects for the rest of the comparisons were much milder. We also examined the distribution of PGS scores across a 5-level severity scale to further determine if there was any correspondence between clinical severity and genetic risk. Median PGS scores were lower in the asymptomatic and mild groups, whereas higher median scores were observed in the moderate, severe, and critical patients (Figure 4). We fitted a multinomial model using the asymptomatic class as reference and calculated the OR for each category (Supplementary Table 13), observing that the disease genetic risk was similar among asymptomatic, mild, and moderate patients. Given that the PGS was built with variants associated with critical disease and/or hospitalization and that the categories severe and critical correspond to hospitalized patients, these results underscore the ability of cross-ancestry PGS for risk stratification

Finally, we incorporated the novel lead SNPs from our AMR meta-analysis (rs13003835, rs2477820, and rs77599934) into the PGS model. Their inclusion in the model contributed to explain a larger variance (R2=1.74%) than the model without them. This result, however, should be taken with caution given the risk of overfitting due to the use of the same subjects both for the derivation and testing of the variants.

DISCUSSION

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

We have conducted the largest GWAS meta-analysis of COVID-19 hospitalization in admixed AMR to date. While the genetic risk basis discovered for COVID-19 is largely shared among populations, trans-ancestry meta-analyses on this disease have primarily included EUR samples. This dominance of GWAS in Europeans, and the subsequent bias in sample sizes, can mask population-specific genetic risks (i.e., variants that are monomorphic in some populations) or be less powered to detect risk variants having higher allele frequencies in population groups other than Europeans. In this sense, after combining data from admixed AMR patients, we found two risk loci which are first discovered in a GWAS of Latin-American populations. Interestingly, the sentinel variant rs77599934 in the DDIAS gene is a rare coding variant (~1% for allele G) with a large effect on COVID-19 hospitalization that is nearly monomorphic in most of the other populations. This has likely led to its exclusion from the cross-populations metaanalyses conducted to date, remaining undetectable. Fine mapping of the region harbouring DDIAS did not reveal further information about which gene could be the more prone to be causal, or about the functional consequences of the risk variant. However, DDIAS, known as damage-induced apoptosis suppressor gene, is itself a plausible candidate gene. It has been linked to DNA damage repair

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

mechanisms: research showed that depletion of DDIAS led to an increase of ATM phosphorylation and the formation of p53-binding protein (53BP1) foci, a known biomarker of DNA double-strand breaks, suggesting a potential role in double-strand break repair¹⁹. Similarly, elevated levels of phosphorylated nuclear histone 2AXγ were detected after knocking down *DDIAS*, further emphasizing its role in DNA damage²⁰. Interestingly, a study found that the infection by SARS-CoV-2 also triggered the phosphorylation of the ATM kinase and inhibited repair mechanisms, causing the accumulation of DNA damage²¹. This same study reported the activation of the proinflammatory pathway p38/MAPK by the virus, which was as well prompted after knocking-down *DDIAS*²⁰. Regarding lung function, the role of DDIAS in lung cancer has been widely studied. It has been proposed as a potential biomarker for lung cancer after finding that it interacts with STAT3 in lung cancer cells, regulating IL-6^{22,23} and thus mediating inflammatory processes. Furthermore, another study determined that its blockade inhibited lung cancer cell growth²⁰. The sentinel variant was in strong LD with an eQTL that reduced gene expression of DDIAS in lung, and our findings suggest that DDIAS gene may be indeed involved in viral response. Hence, one reasonable hypothesis is that reduced expression of DDIAS could potentially facilitate SARS-CoV-2 infection through the downregulation of pathways involved in DNA repairment and inflammation. Another prioritized gene from this region was PRCP, an angiotensinase that has been linked to hypertension and for which a hypothesis on its role on COVID-19 progression has been raised^{24,25}. The risk region found in chromosome 2 prioritized more than one gene. The lead variant rs13003835 is located within BAZ2B. BAZ2B encodes one of the regulatory subunits of the Imitation switch (ISWI) chromatin remodelers²⁶ constituting the BRF-1/BRF-5

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

complexes with SMARCA1 and SMARCA5, respectively, and the association signal colocalized with eQTLs in whole blood. The gene LY75 (encoding the lymphocyte antigen 75) also colocalized with eQTLs in whole blood, esophagus mucosa, and lung tissues. Lymphocyte antigen 75 is involved in immune processes through antigen presentation in dendritic cells and endocytosis²⁷, and has been associated with inflammatory diseases, representing also a compelling candidate for the region. Increased expression of LY75 has been detected within hours after the infection by SARS-CoV- $2^{28,29}$. Lastly, the signal of *CD302* colocalized in individuals with high AFR ancestral admixture in whole blood. This gene is located in the vicinity of LY75 and both conform the readthrough LY75-CD302. It is worth noting that differences in AF for this variant suggest that analyses in AMR populations might be more powered to detect the association, supporting the necessity of population-specific studies. A third novel risk region was observed in chromosome 15, between the genes *IQGAP1* and ZNF774, although not reaching genome-wide significance. Secondary analyses revealed five TWAS-associated genes, some of which have been already linked to severe COVID-19. In a comprehensive multi-tissue gene expression profiling study³⁰, decreased expression of *CAMP* and *S100A8/S100A9* genes in COVID-19 severe patients was observed, while another study detected the upregulation of SCL25A37 among severe COVID-19 patients³¹. SMARCC1 is a subunit of the SWI/SNF chromatin remodelling complex that has been identified as pro-viral for SARS-CoV-2 and other coronavirus strains through a genome-wide screen³². This complex is crucial for ACE2 expression and the viral entry in the cell³³. To explore the genetic architecture of the trait among admixed AMR populations, we performed two cross-ancestry meta-analyses including the SCOURGE Latin-American cohort GWAS findings. We found that the two novel risk variants did not associate with

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

COVID-19 hospitalization outside the population-specific meta-analysis, highlighting the importance of complementing trans-ancestry meta-analyses with group-specific analyses. Notably, this analysis did not replicate the association at the DSTYK locus, which was associated with severe COVID-19 in Brazilian individuals with higher European admixture³⁴. This lack of replication supports the initial hypothesis of that study suggesting that the risk haplotype derived from European populations, as we have reduced the weight of this ancestral contribution in our study by excluding those individuals. Moreover, these cross-ancestry meta-analyses pointed to three loci that were not genome-wide significant in the HGIv7 ALL meta-analysis: a novel locus at CREBBP, and two loci at ZBTB7A and CASC20 that were reported in another meta-analysis. CREBBP and ZBTB7A achieved a stronger significance when considering only EUR, AFR, and admixed AMR GIA groups. According to a recent study, elevated levels of the ZBTB7A gene promote a quasi-homeostatic state between coronaviruses and host cells, preventing cell death by regulating oxidative stress pathways³⁵. This gene is involved in several signalling pathways, such as B and T cell differentiation³⁶. On a separate note, CREBBP encodes the CREB binding protein (CBP), involved in transcription activation, that is known to positively regulate the type I interferon response through virus-induced phosphorylation of IRF-3³⁷. Besides, the CREBP/CBP interaction has been implicated in SARS-CoV-2 infection³⁸ via the cAMP/PKA pathway. In fact, cells with suppressed CREBBP gene expression exhibit reduced replication of the so called Delta and Omicron SARS-CoV-2 variants³⁸. The cross-population PGS model effectively stratified individuals based on their genetic risk and demonstrated consistency with the clinical severity classification of the patients. The inclusion of the new variants in the PGS model slightly improved the

predictive value of the PGS. However, it is important to confirm this last finding in an external admixed AMR cohort to address potential overfitting arising from using the same individuals both for the discovery of the associations and for testing the model. This study is subject to limitations, mostly concerning the sample recruitment and composition. The SCOURGE Latino-American sample size is small and the GWAS is underpowered. Another limitation is the difference in case-control recruitment across sampling regions that, yet controlled for, may reduce the ability to observe significant associations driven by different compositions of the populations. In this sense, the identified risk loci might not replicate in a cohort lacking any of the parental population sources from the three-way admixture. Likewise, we could not explicitly control for socio-environmental factors that could have affected COVID-19 spread and hospitalization rates, although genetic principal components are known to capture nongenetic factors. Finally, we must acknowledge the lack of a replication cohort. We have used all the available GWAS data for COVID-19 hospitalization in admixed AMR in this meta-analysis due to the low number of studies conducted. Therefore, we had no studies to replicate or validate the results. These concerns may be addressed in the future by including more AMR GWAS studies in the meta-analysis, both by involving diverse populations in study designs and by supporting research from countries in Latin-America. This study provides novel insights into the genetic basis of COVID-19 severity, emphasizing the importance of considering host genetic factors through using non-European populations, especially of admixed sources. Such complementary efforts can pin down new variants and increase our knowledge on the host genetic factors of severe COVID-19.

Materials and methods

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

GWAS in Latin Americans from SCOURGE

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

The SCOURGE Latin American cohort A total of 3,729 of COVID-19 positive cases were recruited across five countries from Latin America (Mexico, Brazil, Colombia, Paraguay, and Ecuador) by 13 participating centres (supplementary Table 1) from March 2020 to July 2021. In addition, we included 1,082 COVID-19 positive individuals recruited between March and December 2020 in Spain who either had evidence of origin from a Latin American country or showed inferred genetic admixture between AMR, EUR, and AFR (with < 0.05% SAS/EAS). These individuals were excluded from a previous SCOURGE study that focused on participants with European genetic ancestries¹⁶. We used hospitalization as a proxy for disease severity and defined as cases those COVID-19 positive patients that underwent hospitalization as a consequence of the infection and used as controls those that did not need hospitalization due to COVID-19. Samples and data were collected with informed consent after the approval of the Ethics and Scientific Committees from the participating centres and by the Galician Ethics Committee Ref 2020/197. Recruitment of patients from IMSS (in Mexico, City), was approved by of the National Comitte of Clinical Research, from Instituto Mexicano del Seguro Social, Mexico (protocol R-2020-785-082). Samples and data were processed following normalized procedures. The REDCap electronic data capture tool^{39,40}, hosted at Centro de Investigación Biomédica en Red (CIBER) from the Instituto de Salud Carlos III (ISCIII), was used to collect and manage demographic, epidemiological, and clinical variables. Subjects were diagnosed for COVID-19 based on quantitative PCR tests (79.3%), or according to clinical (2.2%) or laboratory procedures (antibody tests: 16.3%; other microbiological tests: 2.2%).

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

SNP array genotyping Genomic DNA was obtained from peripheral blood and isolated using the Chemagic DNA Blood 100 kit (PerkinElmer Chemagen Technologies GmbH), following the manufacturer's recommendations. Samples were genotyped with the Axiom Spain Biobank Array (Thermo Fisher Scientific) following the manufacturer's instructions in the Santiago de Compostela Node of the National Genotyping Center (CeGen-ISCIII; http://www.usc.es/cegen). This array contains probes for genotyping a total of 757,836 SNPs. Clustering and genotype calling were performed using the Axiom Analysis Suite v4.0.3.3 software. Quality control steps and variant imputation A quality control (QC) procedure using PLINK 1.9⁴¹ was applied to both samples and the genotyped SNPs. We excluded variants with a minor allele frequency (MAF) <1%, a call rate <98%, and markers strongly deviating from Hardy-Weinberg equilibrium expectations ($p<1x10^{-6}$) with mid-p adjustment. We also explored the excess of heterozygosity to discard potential cross-sample contaminations. Samples missing >2% of the variants were filtered out. Subsequently, we kept the autosomal SNPs and removed high LD regions and conducted LD-pruning (windows of 1,000 SNPs, with step size of 80 and r^2 threshold of 0.1) to assess kinship and estimate the global ancestral proportions. Kinship was evaluated based on IBD values, removing one individual from each pair with PI HAT>0.25 that showed a Z0, Z1, and Z2 coherent pattern (according to the theoretical expected values for each relatedness level). Genetic principal components (PCs) were calculated with PLINK with the subset of LD pruned variants.

648

649

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

Genotypes were imputed with the TOPMed version r2 reference panel (GRCh38) using the TOPMed Imputation Server and variants with Rsq<0.3 or with MAF<1% were filtered out. A total of 4,348 individuals and 10,671,028 genetic variants were included in the analyses. Genetic admixture estimation Global genetic inferred ancestry (GIA), referred to the genetic similarity to the used reference individuals, was estimated with the ADMIXTURE⁴² v1.3 software following a two-step procedure. First, we randomly sampled 79 European (EUR) and 79 African (AFR) samples from The 1000 Genomes Project (1KGP)⁴³ and merged them with the 79 Native American (AMR) samples from Mao et al. 44 keeping the biallelic SNPs. LDpruned variants were selected from this merge using the same parameters as in the QC. We then run an unsupervised analysis with K=3 to redefine and homogenize the clusters and to compose a refined reference for the analyses, by applying a threshold of ≥95% of belonging to a particular cluster. As a result of this, 20 AFR, 18 EUR, and 38 AMR individuals were removed. The same LD-pruned variants data from the remaining individuals were merged with the SCOURGE Latin American cohort to perform a supervised clustering and estimated admixture proportions. A total of 471 samples from the SCOURGE cohort with >80% estimated European GIA were removed to reduce the weight of the European ancestral component, leaving a total of 3,512 admixed American (AMR) subjects for downstream analyses. Association analysis Results for the SCOURGE Latin Americans GWAS were obtained testing for COVID-19 hospitalization as a surrogate of severity. To accommodate the continuum of GIA in the cohort, we opted for a joint testing of all the individuals as a single study using a

672

673

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

mixed regression model, as this approach has demonstrated a greater power and to sufficiently control population structure⁴⁵. The SCOURGE cohort consisted of 3,512 COVID-19 positive patients: cases (n=1,625) were defined as hospitalized COVID-19 patients and controls (n=1,887) as non-hospitalized COVID-19 positive patients. Logistic mixed regression models were fitted using the SAIGEgds⁴⁶ package in R, which implements the two-step mixed SAIGE⁴⁷ model methodology and the SPA test. Baseline covariables included sex, age, and the first 10 PCs. To account for a potential heterogeneity in the recruitment and hospitalization criteria across the participating countries, we adjusted the models by groups of the recruitment areas classified in six categories: Brazil, Colombia, Ecuador, Mexico, Paraguay, and Spain. This dataset has not been used in any previously GWAS of COVID-19 published to date. **Meta-analysis of Latin-American populations** The results of the SCOURGE Latin American cohort were meta-analyzed with the AMR HGI-B2 data, conforming our primary analysis. Summary results from the HGI freeze 7 B2 analysis corresponding to the admixed AMR population were obtained from the public repository (April 8, 2022: https://www.covid19hg.org/results/r7/), summing up 3,077 cases and 66,686 controls from seven contributing studies. We selected the B2 phenotype definition because it offered more power and the presence of population controls not ascertained for COVID-19 does not have a drastic impact in the association results. The meta-analysis was performed using an inverse-variance weighting method in METAL⁴⁸. Average allele frequency was calculated and variants with low imputation quality (Rsq<0.3) were filtered out, leaving 10,121,172 variants for meta-analysis.

695

696

697

698

699

700

701

702

703

704

705

706

707

708

709

710

711

712

713

714

715

716

717

Heterogeneity between studies was evaluated with the Cochran's-Q test. The inflation of results was assessed based on a genomic control (lambda). Definition of the genetic risk loci and putative functional impact Definition of lead variant and novel loci To define the lead variants in the loci that were genome-wide significant, an LDclumping was performed on the meta-analysis data using a threshold p-value<5x10⁻⁸, clump distance=1500 kb, independence set at a threshold r²=0.1 and used the SCOURGE cohort genotype data as LD reference panel. Independent loci were deemed as a novel finding if they met the following criteria: 1) p-value<5x10⁻⁸ in the metaanalysis and p-value>5x10⁻⁸ in the HGI B2 ALL meta-analysis or in the HGI B2 AMR and AFR and EUR analyses when considered by separate; 2) Cochran's Q-test for heterogeneity of effects is $<0.05/N_{loci}$, where N_{loci} is the number of independent variants with p<5x10⁻⁸; and 3) the nearest gene has not been previously described in the latest HGIv7 update. Annotation and initial mapping Functional annotation was done with FUMA⁴⁹ for those variants with a p-value<5x10⁻⁸ or in moderate-to-strong LD (r²>0.6) with the lead variants, where the LD was calculated from the 1KGP AMR panel. Genetic risk loci were defined by collapsing LD-blocks within 250 kb. Then, genes, scaled CADD v1.4 scores, and RegulomeDB v1.1 scores were annotated for the resulting variants with ANNOVAR in FUMA⁴⁹. Gene-based analysis was also performed using MAGMA⁵⁰ as implemented in FUMA, under the SNP-wide mean model using the 1KGP AMR reference panel. Significance was set at a threshold p<2.66x10⁻⁶ (which assumes that variants can be mapped to a total of 18,817 genes).

719

720

721

722

723

724

725

726

727

728

729

730

731

732

733

734

735

736

737

738

739

740

741

FUMA allowed us to perform an initial gene mapping by two approaches: (1) positional mapping, which assigns variants to genes by physical distance using 10-kb windows; and (2) eQTL mapping based on GTEx v.8 data from whole blood, lungs, lymphocytes, and oesophagus mucosa tissues, establishing a False Discovery Rate (FDR) of 0.05 to declare significance for variant-gene pairs. Subsequently, to assign the variants to the most likely gene driving the association, we refined the candidate genes by fine mapping the discovered regions and implementing functional mapping. To conduct a Bayesian fine mapping, credible sets for the genetic loci considered novel findings were calculated on the results from each of the three meta-analyses to identify a subset of variants most likely containing the causal variant at 95% confidence level, assuming that there is a single causal variant and that it has been tested. We used corrcoverage (https://cran.rstudio.com/web/packages/corrcoverage/index.html) for R to calculate the posterior probabilities of the variant being causal for all variants with an $r^2>0.1$ with the leading SNP and within 1 Mb except for the novel variant in chromosome 19, for which we used a window of 0.5 Mb. Variants were added to the credible set until the sum of the posterior probabilities was ≥0.95. VEP (https://www.ensembl.org/info/docs/tools/vep/index.html) and the V2G aggregate scoring from Open Targets Genetics (https://genetics.opentargets.org) were used to annotate the biological function of the variants contained in the fine-mapped credible sets Colocalization analysis We also conducted colocalization analyses to identify the putative causal genes that could act through the regulation of gene expression. FUMA's eQTL mapping enabled

743

744

745

746

747

748

749

750

751

752

753

754

755

756

757

758

759

760

761

762

763

764

765

the identification of genes whose expression was associated with the variants in whole blood, lungs, lymphocytes, and oesophagus mucosa tissues. We combined this information with the VEP and V2G aggregate scoring to prioritize genes. For the finemapping regions, we included the variants within the calculated credible sets. In the cases where the fine mapping was unsuccessful, we considered variants within a 0.2 Mb window of the lead variant. For each prioritized gene, we then run COLOC⁵¹ to assess the evidence of colocalization between association signals and the eQTLs in each tissue, when at least one variant overlapped between them. COLOC estimates the posterior probability of two traits sharing the same causal variant in a locus. Prior probabilities of a variant being associated to COVID-19 phenotype (p1) and gene expression (p2) were set at 1x10⁻⁴, while pp2 was set at 1x10⁻⁶ as they are robust thresholds⁵². The posterior probability of colocalization (PP4) > 0.75 and a ratio PP4/PP3>3 were used as the criteria to support evidence of colocalization. Additionally, a threshold of PP4.SNP >0.5 was chosen for causal variant prioritization. In cases were colocalization of a single variant failed, we computed the 95% credible sets. The eQTL data was retrieved from GTEx v8 and only significant variant-gene pairs were considered in the analyses. Colocalization in whole-blood was also performed using the recent published gene expression datasets derived from a cohort of African Americans, Puerto Ricans, and Mexican Americans (GALA II-SAGE)⁵³. We used the results from the pooled cohort for the three discovered loci, and from the AFRHp5 (African genetic ancestry>50%) and IAMHp5 (Native American genetic ancestry>50%) cohorts for the risk loci in chromosomes 2 and 11. Results are shown in the Supplementary Table 10. Sensitivity plots are shown in supplementary Figures 4 and 5.

29

Transcription-wide association studies

766

767

768

769

770

771

772

773

774

775

776

777

778

779

780

783

784

785

786

787

788

Transcriptome-wide association studies (TWAS) were conducted using the pretrained prediction models with MASHR-computed effect sizes on GTEx v8 datasets^{54,55}. Results from the Latin-American meta-analysis were harmonized and integrated with the prediction models through S-PrediXcan⁵⁶ for lungs, whole blood, lymphocytes and oesophagus mucosa tissues. Statistical significance was set at p-value<0.05 divided by the number of genes that were tested for each tissue. Subsequently, we leveraged results for all 49 tissues and run a multi-tissue TWAS to improve power for association, as demonstrated recently⁵⁷. TWAS was also conducted with the MASHR models for whole-blood in the pooled admixed AMR from the GALA and SAGE studies⁵³.

Cross-population meta-analyses

We conducted two additional meta-analyses to investigate the ability of combining

populations to replicate our discovered risk loci. This methodology enabled the

comparison of effects and the significance of associations in the novel risk loci between

the results from analyses that included or excluded other population groups.

The first meta-analysis comprised the five populations analysed within HGI (B2-ALL).

Additionally, to evaluate the three GIA components within the SCOURGE Latin-

American cohort⁵⁸, we conducted a meta-analysis of the admixed AMR, EUR, and AFR

cohorts (B2). All summary statistics were retrieved from the HGI repository. We

applied the same meta-analysis methodology and filters as in the admixed AMR meta-

analysis. Novel variants from these meta-analyses were fine-mapped and colocalized

with gene expression.

Cross-population Polygenic Risk Score

790

791

792

793

794

795

796

797

798

799

800

801

802

803

804

805

806

807

808

809

810

811

812

813

A polygenic risk score (PGS) for critical COVID-19 was derived combining the variants associated with hospitalization or disease severity that have been discovered to date. We curated a list of lead variants that were: 1) associated to either severe disease or hospitalization in the latest HGIv7 release¹ (using the hospitalization weights); or 2) associated to severe disease in the latest GenOMICC meta-analysis² that were not reported in the latest HGI release. A total of 49 markers were used in the PGS model (see supplementary Table 13) since two variants were absent from our study. Scores were calculated and normalized for the SCOURGE Latin-American cohort with PLINK 1.9. This cross-ancestry PGS was used as a predictor for hospitalization (COVID-19 positive that were hospitalized vs. COVID-19 positive that did not necessitate hospital admission) by fitting a logistic regression model. Prediction accuracy for the PGS was assessed by performing 500 bootstrap resamples of the increase in the pseudo-R-squared. We also divided the sample in deciles and percentiles to assess risk stratification. The models were fit for the dependent variable adjusting for sex, age, the first 10 PCs, and the sampling region (in the Admixed AMR cohort) with and without the PGS, and the partial pseudo-R2 was computed and averaged among the resamples. A clinical severity scale was used in a multinomial regression model to further evaluate the power of this cross-ancestry PGS for risk stratification. This severity strata were defined as follows: 0) asymptomatic; 1) mild, that is, with symptoms, but without pulmonary infiltrates or need of oxygen therapy; 2) moderate, that is, with pulmonary infiltrates affecting <50% of the lungs or need of supplemental oxygen therapy; 3) severe disease, that is with hospital admission and PaO₂<65 mmHg or SaO₂<90%, PaO₂/FiO₂<300, SaO₂/FiO₂<440, dyspnea, respiratory frequency≥22 bpm, and infiltrates affecting >50% of the lungs; and 4) critical disease, that is with an admission

815

816

817

818

819

820

821

822

823

824

825

826

827

828

829

830

831

832

833

834

835

to the ICU or need of mechanical ventilation (invasive or non-invasive). We also included the novel risk variants as predictors alongside the PRS to determine if they provided increased prediction ability. Data availability Summary statistics from the SCOURGE Latin-American GWAS will be available at https://github.com/CIBERER/Scourge-COVID19. **Funding** Instituto de Salud Carlos III (COV20_00622 to A.C., COV20/00792 to M.B., COV20_00181 to C.A., COV20_1144 to M.A.J.S. and A.F.R., PI20/00876 to C.F.); European Union (ERDF) 'A way of making Europe'. Fundación Amancio Ortega, Banco de Santander (to A.C.), Estrella de Levante S.A. and Colabora Mujer Association (to E.G.-N.) and Obra Social La Caixa (to R.B.); Agencia Estatal de Investigación (RTC-2017-6471-1 to C.F.), Cabildo Insular de Tenerife (CGIEU0000219140 'Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19' to C.F.) and Fundación Canaria Instituto de Investigación Sanitaria de Canarias (PIFIISC20/57 to C.F.). SD-DA was supported by a Xunta de Galicia predoctoral fellowship. **Author contributions** Study design: RC, AC, CF. Data collection: SCOURGE cohort group. Data analysis: SD-DA, RC, ADL, CF, JML-S. Interpretation: SD-DA, RC, ADL. Drafting of the manuscript: SD-DA, RC, ADL, CF, AR-M, AC. Critical revision of the manuscript: 836 SD-DA, RC, ADL, AC, CF, JAR, AR-M, PL. Approval of the final version of the

publication: all co-authors.

Acknowledgements

837

838

- The contribution of the Centro National de Genotipado (CEGEN), and Centro de
- 840 Supercomputación de Galicia (CESGA) for funding this project by providing
- supercomputing infrastructures, is also acknowledged. Authors are also particularly
- grateful for the supply of material and the collaboration of patients, health professionals
- from participating centers and biobanks. Namely Biobanc-Mur, and biobancs of the
- 844 Complexo Hospitalario Universitario de A Coruña, Complexo Hospitalario
- 845 Universitario de Santiago, Hospital Clínico San Carlos, Hospital La Fe, Hospital
- 846 Universitario Puerta de Hierro Majadahonda—Instituto de Investigación Sanitaria
- Puerta de Hierro—Segovia de Arana, Hospital Ramón y Cajal, IDIBGI, IdISBa, IIS
- Biocruces Bizkaia, IIS Galicia Sur. Also biobanks of the Sistema de Salud de Aragón,
- 849 Sistema Sanitario Público de Andalucía, and Banco Nacional de ADN.

References

850

851

- 852 1. Initiative, T. C.-19 H. G. & Ganna, A. A second update on mapping the human genetic
- 853 architecture of COVID-19. 2022.12.24.22283874 Preprint at
- 854 https://doi.org/10.1101/2022.12.24.22283874 (2023).
- 855 2. GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19
- Nature. https://www.nature.com/articles/s41586-023-06034-3.
- 857 3. Niemi, M. E. K. et al. Mapping the human genetic architecture of COVID-19. Nature
- 858 **600**, 472–477 (2021).
- 859 4. Popejoy, A. B. & Fullerton, S. M. Genomics is failing on diversity. *Nature* **538**, 161–164
- 860 (2016).
- 861 5. Sirugo, G., Williams, S. M. & Tishkoff, S. A. The Missing Diversity in Human Genetic
- 862 Studies. Cell 177, 26–31 (2019).

- 863 6. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and
- challenges of mapping in diverse populations. *Genome Med.* **6**, 91 (2014).
- 865 7. Rosenberg, N. A. et al. Genome-wide association studies in diverse populations. Nat.
- 866 Rev. Genet. 11, 356-366 (2010).
- 867 8. Kwok, A. J., Mentzer, A. & Knight, J. C. Host genetics and infectious disease: new tools,
- insights and translational opportunities. *Nat. Rev. Genet.* **22**, 137–153 (2021).
- 869 9. Karlsson, E. K., Kwiatkowski, D. P. & Sabeti, P. C. Natural selection and infectious
- disease in human populations. *Nat. Rev. Genet.* **15**, 379–393 (2014).
- 871 10. Namkoong, H. et al. DOCK2 is involved in the host genetics and biology of severe
- 872 COVID-19. Nature 609, 754-760 (2022).
- 873 11. Bastard, P. et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral
- diseases in homozygotes. *J. Exp. Med.* **219**, e20220028 (2022).
- 875 12. Duncan, C. J. A. et al. Life-threatening viral disease in a novel form of autosomal
- 876 recessive IFNAR2 deficiency in the Arctic. J. Exp. Med. **219**, e20212427 (2022).
- 877 13. Peterson, R. E. et al. Genome-wide Association Studies in Ancestrally Diverse
- 878 Populations: Opportunities, Methods, Pitfalls, and Recommendations. Cell 179, 589-603
- 879 (2019).
- 880 14. Mester, R. et al. Impact of cross-ancestry genetic architecture on GWAS in admixed
- 881 populations. 2023.01.20.524946 Preprint at https://doi.org/10.1101/2023.01.20.524946
- 882 (2023).
- 883 15. Tractor uses local ancestry to enable the inclusion of admixed individuals in GWAS and
- to boost power | Nature Genetics. https://www.nature.com/articles/s41588-020-00766-y.
- 885 16. Cruz, R. et al. Novel genes and sex differences in COVID-19 severity. Hum. Mol. Genet.
- 886 **31**, 3789–3806 (2022).
- 887 17. Degenhardt, F. et al. Detailed stratified GWAS analysis for severe COVID-19 in four
- 888 European populations. *Hum. Mol. Genet.* **31**, 3945–3966 (2022).
- 889 18. Whole-genome sequencing reveals host factors underlying critical COVID-19 | Nature.
- 890 https://www.nature.com/articles/s41586-022-04576-6.
- 891 19. Evolution-based screening enables genome-wide prioritization and discovery of DNA
- repair genes | PNAS. https://www.pnas.org/doi/full/10.1073/pnas.1906559116.
- 893 20. Human Noxin is an anti-apoptotic protein in response to DNA damage of A549
- 894 non-small cell lung carcinoma Won 2014 International Journal of Cancer Wiley Online
- Library. https://onlinelibrary.wiley.com/doi/10.1002/ijc.28600.
- 896 21. Gioia, U. et al. SARS-CoV-2 infection induces DNA damage, through CHK1 degradation
- and impaired 53BP1 recruitment, and cellular senescence. *Nat. Cell Biol.* **25**, 550–564 (2023).
- 898 22. Im, J.-Y. et al. DDIAS promotes STAT3 activation by preventing STAT3 recruitment to
- 899 PTPRM in lung cancer cells. *Oncogenesis* **9**, 1–11 (2020).

- 900 23. Im, J.-Y., Kang, M.-J., Kim, B.-K. & Won, M. DDIAS, DNA damage-induced apoptosis
- 901 suppressor, is a potential therapeutic target in cancer. Exp. Mol. Med. 1–7 (2023)
- 902 doi:10.1038/s12276-023-00974-6.
- 903 24. Angeli, F. et al. The spike effect of acute respiratory syndrome coronavirus 2 and
- 904 coronavirus disease 2019 vaccines on blood pressure. Eur. J. Intern. Med. 109, 12–21 (2023).
- 905 25. Silva-Aguiar, R. P. et al. Role of the renin-angiotensin system in the development of
- 906 severe COVID-19 in hypertensive patients. Am. J. Physiol.-Lung Cell. Mol. Physiol. 319, L596-
- 907 L602 (2020).
- 908 26. Li, Y. et al. The emerging role of ISWI chromatin remodeling complexes in cancer. J.
- 909 Exp. Clin. Cancer Res. 40, 346 (2021).
- 910 27. The Dendritic Cell Receptor for Endocytosis, Dec-205, Can Recycle and Enhance
- 911 Antigen Presentation via Major Histocompatibility Complex Class II—Positive Lysosomal
- 912 Compartments | Journal of Cell Biology | Rockefeller University Press.
- 913 https://rupress.org/jcb/article/151/3/673/21295/The-Dendritic-Cell-Receptor-for-Endocytosis-
- 914 Dec.
- 915 28. Sims, A. C. et al. Release of Severe Acute Respiratory Syndrome Coronavirus Nuclear
- 916 Import Block Enhances Host Transcription in Human Lung Cells. J. Virol. 87, 3885–3902 (2013).
- 917 29. A Network Integration Approach to Predict Conserved Regulators Related to
- Pathogenicity of Influenza and SARS-CoV Respiratory Viruses | PLOS ONE.
- 919 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0069374.
- 920 30. Gómez-Carballa, A. et al. A multi-tissue study of immune gene expression profiling
- 921 highlights the key role of the nasal epithelium in COVID-19 severity. Environ. Res. 210, 112890
- 922 (2022).
- 923 31. Policard, M., Jain, S., Rego, S. & Dakshanamurthy, S. Immune characterization and
- 924 profiles of SARS-CoV-2 infected patients reveals potential host therapeutic targets and SARS-
- 925 CoV-2 oncogenesis mechanism. Virus Res. **301**, 198464 (2021).
- 926 32. Wei, J. et al. Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2
- 927 Infection. Cell 184, 76-91.e13 (2021).
- 928 33. Wei, J. et al. Pharmacological disruption of mSWI/SNF complex activity restricts SARS-
- 929 CoV-2 infection. Nat. Genet. 55, 471–483 (2023).
- 930 34. Pereira, A. C. et al. Genetic risk factors and COVID-19 severity in Brazil: results from
- 931 BRACOVID study. *Hum. Mol. Genet.* **31**, 3021–3031 (2022).
- 932 35. Zhu, X. et al. ZBTB7A promotes virus-host homeostasis during human coronavirus 229E
- 933 infection. *Cell Rep.* **41**, 111540 (2022).
- 934 36. Gupta, S. et al. Emerging role of ZBTB7A as an oncogenic driver and transcriptional
- 935 repressor. Cancer Lett. 483, 22-34 (2020).
- 936 37. Yoneyama, M. et al. Direct triggering of the type I interferon system by virus infection:
- 937 activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J. 17, 1087-
- 938 1095 (1998).

- 939 38. Yang, Q. et al. SARS-CoV-2 infection activates CREB/CBP in cellular cyclic AMP-
- 940 dependent pathways. J. Med. Virol. 95, e28383 (2023).
- 941 39. Harris, P. A. et al. Research electronic data capture (REDCap)—A metadata-driven
- 942 methodology and workflow process for providing translational research informatics support. J.
- 943 Biomed. Inform. 42, 377-381 (2009).
- 944 40. Harris, P. A. et al. The REDCap consortium: Building an international community of
- software platform partners. J. Biomed. Inform. 95, 103208 (2019).
- 946 41. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and Population-
- 947 Based Linkage Analyses. Am. J. Hum. Genet. **81**, 559–575 (2007).
- 948 42. Alexander, D. H., Novembre, J. & Lange, K. Fast model-based estimation of ancestry in
- 949 unrelated individuals. *Genome Res.* **19**, 1655–1664 (2009).
- 950 43. Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74
- 951 (2015).
- 952 44. Mao, X. et al. A Genomewide Admixture Mapping Panel for Hispanic/Latino
- 953 Populations. Am. J. Hum. Genet. **80**, 1171–1178 (2007).
- 954 45. Wojcik, G. L. et al. Genetic analyses of diverse populations improves discovery for
- 955 complex traits. *Nature* **570**, 514–518 (2019).
- 956 46. Zheng, X. & Davis, J. W. SAIGEgds—an efficient statistical tool for large-scale PheWAS
- 957 with mixed models. *Bioinformatics* **37**, 728–730 (2021).
- 958 47. Zhou, W. et al. Efficiently controlling for case-control imbalance and sample
- 959 relatedness in large-scale genetic association studies. *Nat. Genet.* **50**, 1335–1341 (2018).
- 960 48. METAL: fast and efficient meta-analysis of genomewide association scans
- 961 Bioinformatics | Oxford Academic.
- 962 https://academic.oup.com/bioinformatics/article/26/17/2190/198154.
- 963 49. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
- annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
- 965 50. MAGMA: Generalized Gene-Set Analysis of GWAS Data | PLOS Computational Biology.
- 966 https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1004219.
- 967 51. Giambartolomei, C. et al. Bayesian Test for Colocalisation between Pairs of Genetic
- 968 Association Studies Using Summary Statistics. PLOS Genet. 10, e1004383 (2014).
- 969 52. Wallace, C. Eliciting priors and relaxing the single causal variant assumption in
- 970 colocalisation analyses. PLOS Genet. 16, e1008720 (2020).
- 971 53. Kachuri, L. et al. Gene expression in African Americans, Puerto Ricans and Mexican
- 972 Americans reveals ancestry-specific patterns of genetic architecture. *Nat. Genet.* **55**, 952–963
- 973 (2023).
- 974 54. Barbeira, A. N. et al. Exploiting the GTEx resources to decipher the mechanisms at
- 975 GWAS loci. Genome Biol. 22, 49 (2021).
- 976 55. Barbeira, A. N. et al. GWAS and GTEx QTL integration. (2019)
- 977 doi:10.5281/zenodo.3518299.

- 978 56. Barbeira, A. N. *et al.* Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat. Commun.* **9**, 1825 (2018).
- 980 57. Barbeira, A. N. *et al.* Integrating predicted transcriptome from multiple tissues improves association detection. *PLOS Genet.* **15**, e1007889 (2019).
- 982 58. Genome-wide patterns of population structure and admixture among Hispanic/Latino 983 populations | PNAS. https://www.pnas.org/doi/10.1073/pnas.0914618107?url_ver=Z39.88-984 2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed.

Table 1. Demographic characteristics of the SCOURGE Latin-American cohort.

Variable	Non Hospitalized	Hospitalized	
variable	N = 1,887	N = 1,608	
Age – mean years ± SD	39.1 ± 11.9	54.1 ±14.5	
Sex - N (%)			
Female (%)	1253 (66.4)	668 (41.5)	
GIA* – % mean ±SD			
European	54.4 ±16.2	39.4 ± 20.7	
African	15.3 ± 12.7	9.1 ± 11.6	
Native American	30.3 ± 19.8	51.46 ± 26.5	
Comorbidities - N (%)			
Vascular/endocrinological	488 (25.9)	873 (54.3)	
Cardiac	60 (3.2)	150 (9.3)	
Nervous	15 (0.8)	61 (3.8)	
Digestive	14 (0.7)	33 (2.0)	
Onco-hematological	21 (1.1)	48 (3.00)	
Respiratory	76 (4.0)	118 (7.3)	

^{*}Global genetic inferred ancestry.

986

987

988

989

Table 2. Lead independent variants in the admixed AMR GWAS meta-analysis.

SNP rsID chr:pos EA		EA NEA	OR (95% CI)		EAF	EAF	Nearest
	EA			P-value	cases	controls	gene

rs13003835	2:159407982	T	C	1.20 (1.12-1.27)	3.66E-08	0.563	0.429	BAZ2B
rs35731912	3:45848457	T	C	1.65 (1.47-1.85)	6.30E-17	0.087	0.056	LZTFL1
rs2477820	6:41535254	A	T	0.84 (0.79-0.89)	1.89E-08	0.453	0.517	FOXP4-AS1
rs77599934	11:82906875	G	A	2.27 (1.7-3.04)	2.26E-08	0.016	0.011	DDIAS

991 EA: effect allele; NEA: non-effect allele; EAF: effect allele frequency in the SCOURGE study.

Table 3. Novel variants in the SC-HGI_{ALL} and SC-HGI_{3POP} meta-analyses (with respect to HGIv7). Independent signals after LD clumping.

SNP rsID	chr:pos	EA	NEA	OR (95% CI)	P-value	Nearest gene	Analysis
rs76564172	16:3892266	T	G	1.31 (1.19-1.44)	9.64E-09	CREBBP	SC-HGI _{3POP}
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	1.89E-08	ZBTB7A	SC-HGI _{3POP}
rs66833742	19:4063488	T	C	0.94 (0.92-0.96)	2.50E-08	ZBTB7A	SC-HGI _{ALL}
rs2876034	20:6492834	A	T	0.95 (0.93-0.97)	2.83E-08	CASC20	SC-HGI _{ALL}

EA: effect allele; NEA: non-effect allele.

992

995

996

998

999

997 Figure 1. Flow chart of this study.




Figure 2. A) Manhattan plot for the admixed AMR GWAS meta-analysis. Probability thresholds at p=5x10⁻⁸ and p=5x10⁻⁵ are indicated by the horizontal lines. Genome-wide significant associations with COVID-19 hospitalizations were found in chromosome 2 (within *BAZ2B*), chromosome 3 (within *LZTFL1*), chromosome 6 (within *FOXP4*), and chromosome 11 (within *DDIAS*). A Quantile-Quantile plot is shown in supplementary Figure 2. B) Regional association plots for rs1003835 at chromosome 2 and rs77599934 at chromosome 11; C) Allele frequency distribution across The 1000 Genomes Project populations for the lead variants rs1003835 and rs77599934.




Figure 3. Forest plot showing effect sizes and the corresponding confidence intervals for the sentinel variants identified in the AMR meta-analysis across populations. All beta values with their corresponding CIs were retrieved from the B2 population-specific meta-analysis from the HGI v7 release, except for AMR, for which the beta value and IC from the HGI_{AMR}-SCOURGE meta-analysis is represented.





Figure 4. (A) Polygenic risk stratified by PGS deciles comparing each risk group against the lowest risk group (OR-95%CI); (B) Distribution of the PGS scores in each

of the severity scale classes (0-Asymptomatic, 1-Mild disease, 2-Moderate disease, 3-Severe disease, 4-Critical disease).




Supplementary Material for: Novel risk loci for COVID-19 hospitalization among admixed American populations


Supplementary Tables are provided in a separate excel file

Supplementary figures


Supplementary Figure 1. Global Genetic Inferred Ancestry (GIA) composition in the SCOURGE Latin-American cohort. European (EUR), African (AFR) and Native American (AMR) GIA was derived with ADMIXTURE from a reference panel composed of Aymaran, Mayan, Nahuan, and Quechuan individuals of Native-American genetic ancestry and randomly selected samples from the EUR and AFR 1KGP populations. The colours represent the different geographical sampling regions from which the admixed American individuals from SCOURGE were recruited.



Supplementary Figure 2. Quantile-Quantile plot for the AMR GWAS metaanalysis. A lambda inflation factor of 1.015 was obtained.




Supplementary Figure 3. Regional association plots for the fine mapped loci in chromosomes 2 (upper panel) and 16 (lower panel). Coloured in red, the variants allocated to the credible set at the 95% confidence according to the Bayesian fine mapping. In blue, the sentinel variant.





Supplementary Figure 4. Sensitivity plots from COLOC with expression data from GTEx v8. The range of p12 values (probability that a SNP is associated with both traits) for which the rule H₄>0.7 is supported is shown in green in the right plots for each analysis. Plots in the left represent the variants included in the risk region common to both traits along their individual association -log10(p-values) for each trait, whereas the shading shows the posterior probability that the SNP is causal given H₄ is true. Trait 1 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene expression in each analysis.

LY75 in whole blood











LY75 in esophagus mucosa




Supplementary Figure 5. Sensitivity plots from COLOC with whole blood expression data from the GALA and SAGE II studies in AMR individuals. *AFRhp5* corresponds to the expression dataset computed in individuals with high African ancestries; *AMRhp5* corresponds to the expression dataset computed individuals with high AMR ancestries; *pooled* corresponds to the dataset computed with the total of individuals from the study. In the right, the plots show in green the range of p12 values (probability that a SNP is associated with both traits) for which the rule H₄>0.7 is supported. Plots in the left represent the variants included in the risk region common to both traits along their individual association -log10(p-values) for each trait, whereas the shading shows the posterior probability that the SNP is causal given H₄ is true. Trait 1 corresponds to COVID-19 hospitalization, while trait 2 corresponds to gene expression.

CD302 in whole blood AFRhp5




BAZ2B in whole blood AFRhp5

1086




WDSUB1 in whole blood AFRhp5




LY75 in whole blood AFRhp5

1088




LY75 in whole blood AMRhp5




LY75 in whole blood pooled


1090



CD302 in whole blood pooled



Supplementary Figure 6. Gene-tissue pairs for which either rs1003835 or rs60606421 are significant eQTLs at FDR<0.05 (data retrieved from https://gtexportal.org/home/snp/). rs1003835 (chromosome 2) maps to *BAZ2B*, *LY75*, and *PLA2R* genes. As for the lead variant of chromosome 11, rs77599934, since it was not an eQTL, we used an LD proxy variant (rs60606421). *DDIAS* and *PRCP* genes map closely to this variant. NES and p-values correspond to the normalized effect size (and direction) of eQTL-gene associations and the p-value for the tissue, respectively.



Scourge Cohort Group

1103

1104

1105

1106

Full list of cohort members and affiliations

Javier Abellan^{1,2}; René Acosta-Isaac³; Jose María Aguado^{4,5,6,7}; Carlos Aguilar⁸; Sergio Aguilera-Albesa^{9,10}; Abdolah Ahmadi Sabbagh¹¹; Jorge Alba¹²; Sergiu Albu^{13,14,15}; Karla A.M. Alcalá-Gallardo¹⁶; Julia Alcoba-Florez¹⁷; Sergio Alcolea Batres¹⁸; Holmes Rafael Algarin-Lara^{19,20}; Virginia Almadana²¹; Julia Almeida^{22,23,24,25}; Berta Almoguera^{26,27}; María R. Alonso²⁸; Nuria Alvarez²⁸; Rodolfo Alvarez-Sala Walther¹⁸; Mónica T. Andrade^{29,30}; Álvaro Andreu-Bernabeu^{31,6}; Maria Rosa Antonijoan³²; Eunate

- 1113 Arana-Arri^{33,34}; Carlos Aranda^{35,36}; Celso Arango^{31,37,6}; Carolina Araque^{38,39}; Nathalia
- 1114 K. Araujo⁴⁰; Izabel M.T. Araujo⁴¹; Ana C. Arcanjo^{42,43,44}; Ana Arnaiz^{45,46,47}; Francisco
- 1115 Arnalich Fernández⁴⁸; María J. Arranz⁴⁹; José Ramon Arribas Lopez⁴⁸; Maria-Jesus
- 1116 Artiga⁵⁰; Yubelly Avello-Malaver⁵¹; Carmen Ayuso^{26,27}; Ana Margarita Baldión⁵¹;
- Belén Ballina Martín¹¹; Raúl C. Baptista-Rosas^{52,53,54}; Andrea Barranco-Díaz²⁰; María
- Barreda- Sánchez^{55,56}; Viviana Barrera-Penagos⁵¹; Moncef Belhassen-Garcia^{57,58};
- Enrique Bernal⁵⁵; David Bernal-Bello⁵⁹; Joao F. Bezerra⁶⁰; Marcos A.C. Bezerra⁶¹;
- Natalia Blanca-López⁶²; Rafael Blancas⁶³; Lucía Boix-Palop⁶⁴; Alberto Borobia⁶⁵; Elsa
- Bravo⁶⁶; María Brion^{67,68}; Óscar Brochado-Kith^{69,7}; Ramón Brugada^{70,71,68,72}; Matilde
- Bustos⁷³; Alfonso Cabello⁷⁴; Juan J. Caceres-Agra⁷⁵; Esther Calbo⁷⁶; Enrique J.
- 1123 Calderón^{77,78,79}; Shirley Camacho⁸⁰; Cristina Carbonell^{81,58}; Servando Cardona-
- Huerta⁸²; Antonio Augusto F. Carioca⁸³; Maria Sanchez Carpintero^{35,36}; Carlos Carpio
- 1125 Segura¹⁸; Thássia M.T. Carratto⁸⁴; José Antonio Carrillo-Avila⁸⁵; Maria C.C.
- 1126 Carvalho⁸⁶; Carlos Casasnovas^{87,88,27}; Luis Castano^{33,34,27,89,90}; Carlos F. Castaño^{35,36};
- Jose E. Castelao⁹¹; Aranzazu Castellano Candalija⁹²; María A. Castillo⁸⁰; Yolanda
- 1128 Cañadas³⁶; Francisco C. Ceballos²⁷; Jessica G. Chaux³⁹; Walter G. Chaves-
- Santiago^{93,39}; Sylena Chiquillo-Gómez^{19,20}; Marco A. Cid-Lopez¹⁶; Oscar Cienfuegos-
- 1130 Jimenez⁸²; Rosa Conde-Vicente⁹⁴; M. Lourdes Cordero-Lorenzana⁹⁵; Dolores
- 1131 Corella^{96,97}; Almudena Corrales^{98,99}; Jose L. Cortes-Sanchez^{82,100}; Marta Corton^{26,27};
- 1132 Tatiana X. Costa¹⁰¹; Raquel Cruz^{27,102}; Marina S. Cruz⁴⁰; Luisa Cuesta¹⁰³; Gabriela C.R.
- 1133 Cunha¹⁰⁴; David Dalmau^{105,76}; Raquel C.S. Dantas-Komatsu⁴⁰; M. Teresa Darnaude¹⁰⁶;
- Alba De Martino-Rodríguez^{107,108}; Juan De la Cruz Troca^{109,110,78}; Juan Delgado-
- 1135 Cuesta¹¹¹; Aranzazu Diaz de Bustamante¹⁰⁶; Covadonga M. Diaz-Caneja^{31,37,6}; Beatriz
- Dietl⁷⁶; Silvia Diz-de Almeida^{27,102}; Elena Domínguez-Garrido¹¹²; Alice M. Duarte⁴¹;
- Anderson Díaz-Pérez²⁰; Jose Echave-Sustaeta¹¹³; Rocío Eiros¹¹⁴; César O. Enciso-
- Olivera^{38,39}; Gabriela Escudero¹¹⁵; Pedro Pablo España¹¹⁶; Gladys Mercedes Estigarribia
- Sanabria¹¹⁷; María Carmen Fariñas^{45,46,47}; Marianne R. Fernandes^{118,119}; Lidia
- 1140 Fernandez-Caballero^{26,27}; María J. Fernandez-Nestosa¹²⁰; Ramón Fernández^{45,121}; Silvia
- 1141 Fernández Ferrero¹¹; Yolanda Fernández Martínez¹¹; Ana Fernández-Cruz¹²²; Uxía
- 1142 Fernández-Robelo¹²³; Amanda Fernández-Rodríguez^{69,7}; Marta Fernández-
- Sampedro^{45,47,46}; Ruth Fernández-Sánchez^{26,27}; Tania Fernández-Villa^{124,78}; Carmen
- Fernéndez Capitán⁹²; Patricia Flores-Pérez¹²⁵; Vicente Friaza^{78,79}; Lácides Fuenmayor-
- Hernández²⁰; Marta Fuertes Núñez¹¹; Victoria Fumadó¹²⁶; Ignacio Gadea¹²⁷; Lidia
- Gagliardi^{35,36}; Manuela Gago-Domínguez^{128,129}; Natalia Gallego¹³⁰; Cristina Galoppo¹³¹;
- 1147 Carlos Garcia-Cerrada^{1,2,132}; Josefina Garcia-García⁵⁵; Inés García^{26,27}; Mercedes
- 1148 García^{35,36}; Leticia García^{35,36}; María Carmen García Torrejón^{133,2}; Irene García-
- García⁶⁵; Carmen García-Ibarbia^{45,47,46}; Andrés C. García-Montero¹³⁴; Ana García-
- 1150 Soidán¹³⁵; Elisa García-Vázquez⁵⁵; Aitor García-de-Vicuña^{33,136}; Emiliano Garza-
- Frias⁸²; Jesus Gaytán-Martínez¹³⁷, Angela Gentile¹³¹; Belén Gil-Fournier¹³⁸; Fernan
- Gonzalez Bernaldo de Quirós¹³⁹; Manuel Gonzalez-Sagrado⁹⁴; Hugo Gonzalo Benito¹⁴⁰;
- Beatriz González Álvarez 107,108; Anna González-Neira 28; Javier González-Peñas 31,6,37;
- Oscar Gorgojo-Galindo¹⁴¹; Florencia Guaragna¹³¹; Genilson P. Guegel¹⁴²; Beatriz
- Guillen-Guio⁹⁸; Encarna Guillen-Navarro^{55,143,144,27}; Pablo Guisado-Vasco¹¹³; Luz D.
- Gutierrez-Castañeda^{145,39}; Juan F. Gutiérrez-Bautista¹⁴⁶; Luis Gómez Carrera¹⁸; María

- Gómez García¹²⁸; Ángela Gómez Sacristán¹⁴⁷; Javier Gómez-Arrue^{107,108}; Mario 1157
- Gómez-Duque^{93,39}; Miguel Górgolas⁷⁴; Sarah Heili-Frades¹⁴⁸; Estefania Hernandez¹⁴⁹; 1158
- Luis D. Hernandez-Ortega^{150,151}; Cristina Hernández Moro¹¹; Guillermo Hernández-1159
- Pérez⁸¹; Rebeca Hernández-Vaquero¹⁵²; Belen Herraez²⁸; M. Teresa Herranz⁵⁵; María 1160
- Herrera^{35,36}; María José Herrero^{153,154}; Antonio Herrero-Gonzalez¹⁵⁵; Juan P. 1161
- Horcajada^{156,157,14,158,7}; Natale Imaz-Ayo³³; Maider Intxausti-Urrutibeaskoa¹⁵⁹; Rafael H. 1162
- Jacomo¹⁶⁰; Rubén Jara⁵⁵; Perez Maria Jazmin¹³¹; María A. Jimenez-Sousa^{69,7}; Ángel 1163
- Jiménez^{35,36}; Pilar Jiménez¹⁴⁶; Ignacio Jiménez-Alfaro¹⁶¹; Iolanda Jordan^{162,163,78}; Rocío 1164
- Laguna-Goya^{164,165}; Daniel Laorden¹⁸; María Lasa-Lazaro^{164,165}; María Claudia 1165
- Lattig^{80,166}; Ailen Lauriente¹³¹; Anabel Liger Borja¹⁶⁷; Lucía Llanos¹⁶⁹; Esther Lopez-1166
- Garcia^{109,110,78,170}; Rosario Lopez-Rodriguez^{26,27}; Leonardo Lorente¹⁷¹; José E. 1167
- Lozano¹⁷²; María Lozano-Espinosa¹⁶⁷; Andre D. Luchessi¹⁷³; Eduardo López 1168
- Granados 174,175,27; Amparo López-Bernús 81,58; Miguel A. López-Ruz 176,177,178; Aluísio X. 1169
- Magalhães-Brasil ¹⁷⁹;Ignacio Mahillo ^{180,181,99}; Esther Mancebo ^{164,165}; Carmen Mar ¹¹⁶; 1170
- Cristina Marcelo Calvo⁹²; Miguel Marcos^{81,58}; Alba Marcos-Delgado¹²⁴; Pablo Mariscal 1171
- Aguilar¹⁸; Marta Martin-Fernandez¹⁸²; Laura Martin-Pedraza⁶²; Amalia Martinez¹⁸³; 1172
- Iciar Martinez-Lopez 184,185; Oscar Martinez-Nieto 51,166; Pedro Martinez-Paz 140; Angel 1173
- Martinez-Perez¹⁸⁶; Michel F. Martinez-Resendez⁸²; María M. Martín¹⁸⁷; María Dolores 1174
- Martín¹⁸⁸; Vicente Martín^{124,78}; Caridad Martín-López¹⁶⁷; José-Ángel Martín-1175
- Oterino^{81,58}; María Martín-Vicente⁶⁹; Ricardo Martínez¹⁴⁹; Juan José Martínez^{88,27}; 1176
- Silvia Martínez^{45,47}; Violeta Martínez Robles¹¹; Eleno Martínez-Aquino¹⁸⁹; Óscar 1177
- Martínez-González¹⁹⁰; Andrea Martínez-Ramas^{26,27}; Laura Marzal^{26,27}; Alicia Marín 1178
- Candon⁶⁵; Jose Antonio Mata-Marin, ¹³⁷ Juliana F. Mazzeu^{179,191,192}; Jeane F.P. 1179
- Medeiros⁴⁰; Francisco J. Medrano^{77,78,79}; Xose M. Meijome^{193,194}; Natalia Mejuto-1180
- Montero¹⁹⁵; Celso T. Mendes-Junior ^{84,196,197}; Humberto Mendoza Charris^{66,20}; Eleuterio 1181
- Merayo Macías ¹⁹⁸; Fátima Mercadillo ¹⁹⁹; Arieh R. Mercado-Sesma ^{150,151}; Pablo 1182
- Minguez^{26,27}; Antonio J J. Molina^{124,78}; Elena Molina-Roldán²⁰⁰; Juan José Montoya¹⁴⁹; 1183
- Patricia Moreira-Escriche²⁰¹; Xenia Morelos-Arnedo^{66,20}; Victor Moreno Cuerda^{1,2}; 1184
- Alberto Moreno Fernández⁹²; Antonio Moreno-Docón⁵⁵; Junior Moreno-Escalante²⁰; 1185
- Rubén Morilla^{79,202}; Patricia Muñoz García^{203,99,6}; Ana Méndez-Echevarria²⁰⁴; Pablo 1186
- Neira¹³¹; Julian Nevado^{27,131,205}; Israel Nieto-Gañán¹³⁵; Joana F.R. Nunes⁴²; Rocio 1187
- Nuñez-Torres²⁸; Antònia Obrador-Hevia^{206,207}; J. Gonzalo Ocejo-Vinyals^{45,47}; Virginia Olivar¹³¹; Silviene F. Oliveira^{179,208,208,210,211}; Lorena Ondo^{26,27}; Alberto Orfao^{22,23,24,25}; 1188
- 1189
- Luis Ortega²¹²; Eva Ortega-Paino⁵⁰; Fernando Ortiz-Flores^{45,47}; Rocio Ortiz-Lopez^{213,82}; 1190
- José A. Oteo^{12,214}; Harry Pachajoa^{215,216}; Manuel Pacheco¹⁴⁹; Fredy Javier Pacheco-1191
- Miranda²⁰; Irene Padilla Conejo¹¹; Sonia Panadero-Fajardo⁸⁵; Mara Parellada^{31,37,6}; 1192
- Roberto Pariente-Rodríguez¹³¹; Estela Paz-Artal^{164,165,217}; Germán Peces-Barba^{218,99}; 1193
- Miguel S. Pedromingo Kus²¹⁹; Celia Perales¹²⁷; Patricia Perez²²⁰; Gustavo Perez-de-1194
- Nanclares^{33,221}; Teresa Perucho²²²; Aline Pic-Taylor ^{42,208,209,211}, Lisbeth A. Pichardo¹¹; 1195
- Mel·lina Pinsach-Abuin^{70,68}; Luz Adriana Pinzón^{93,39}; Guillermo Pita³⁰; Francesc Pla-1196
- Junca^{223,27}; Laura Planas-Serra^{88,27}; Ericka N. Pompa-Mera^{224,137}; Gloria L. Porras-1197
- Hurtado¹⁴⁹; Aurora Pujol^{88,27,225}; César Pérez²²⁶; Felipe Pérez-García^{227,228}; Patricia 1198
- Pérez-Matute²¹⁴; Alexandra Pérez-Serra^{70,68}; M. Elena Pérez-Tomás⁵⁵; María Eugenia 1199
- Quevedo Chávez^{19,20}; Maria Angeles Quijada^{30,229}; Inés Quintela¹²⁸; Diana Ramirez-1200

- 1201 Montaño²³⁰; Soraya Ramiro León¹³¹; Pedro Rascado Sedes²³¹; Delia Recalde^{107,108};
- 1202 Emma Recio-Fernández²¹⁴; Salvador Resino^{69,7}; Adriana P. Ribeiro^{29,30,232}; Carlos S.
- 1203 Rivadeneira-Chamorro³⁹; Diana Roa-Agudelo⁵¹; Montserrat Robelo Pardo²³¹; Marilyn
- Johanna Rodriguez³⁹; German Ezequiel Rodriguez Novoa¹³¹; Fernando Rodriguez-
- 1205 Artalejo 109,110,78,170; Carlos Rodriguez-Gallego 233,234; José A. Rodriguez-Garcia 11; María
- 1206 A. Rodriguez-Hernandez⁷³; Antonio Rodriguez-Nicolas¹⁴⁶; Agustí Rodriguez-
- 1207 Palmero^{235,88}; Paula A. Rodriguez-Urrego⁵¹; Belén Rodríguez Maya¹; Marena
- 1208 Rodríguez-Ferrer²⁰; Emilio Rodríguez-Ruiz^{231,129}; Federico Rojo^{236,25}; Andrea Romero-
- 1209 Coronado²⁰; Filomeno Rondón García¹¹; Lidia S. Rosa²³⁶; Antonio Rosales-Castillo²³⁷;
- 1210 Cladelis Rubio^{238,239}; María Rubio Olivera^{35,36}; Montserrat Ruiz^{88,27}; Francisco Ruiz-
- 1211 Cabello^{146,177,240}; Eva Ruiz-Casares²²²; Juan J. Ruiz-Cubillan^{45,47}; Javier Ruiz-
- Hornillos^{241,36,242}; Pablo Ryan^{243,244,245,7}; Hector D. Salamanca^{38,39}; Lorena Salazar-
- 1213 García⁸⁰; Giorgina Gabriela Salgueiro Origlia ⁹²; Cristina Sancho-Sainz¹⁵⁹; Jorge Luis
- 1214 Sandoval-Ramírez, ¹³⁷ Anna Sangil⁶⁴; Arnoldo Santos²²⁶; Ney P.C. Santos¹¹⁸; Amanda
- 1215 C.M. Saúde ^{30,246} Agatha Schlüter ^{88,27}; Sonia Segovia ^{223,247,248}; Alex Serra-Llovich ²⁴⁹;
- 1216 Fernando Sevil Puras⁸; Marta Sevilla Porras^{27,130}; Miguel A. Sicolo^{250,251}; Vivian N.
- 1217 Silbiger¹⁷³; Nayara S. Silva²⁵²; Fabiola T.C. Silva⁴⁰; Cristina Silván Fuentes²⁷; Jordi
- 1218 Solé-Violán^{253,99,254}; José Manuel Soria¹⁸⁶; Jose V. Sorlí^{96,97}; Renata R. Sousa¹⁷⁹; Juan
- 1219 Carlos Souto³; Karla S.C. Souza⁸⁶; Vanessa S. Souza¹⁰⁴; John J. Sprockel^{93,39}; David A.
- 1220 Suarez-Zamora⁵¹; José Javier Suárez-Rama¹²⁸; Pedro-Luis Sánchez^{114,58}; Antonio J.
- 1221 Sánchez López²⁵⁵; María Concepción Sánchez Prados¹⁸; Javier Sánchez Real¹¹; Jorge
- 1222 Sánchez Redondo^{1,256}; Clara Sánchez-Pablo¹¹⁴; Olga Sánchez-Pernaute²⁵⁷; Xiana
- 1223 Taboada-Fraga¹⁹⁵; Eduardo Tamayo^{258,140,7}; Alvaro Tamayo-Velasco²⁵⁹; Juan Carlos
- 1224 Taracido-Fernandez¹⁵⁵; Nathali A.C. Tavares²⁶⁰; Carlos Tellería^{107,108}; Jair Antonio
- 1225 Tenorio Castaño^{27,130,205}; Alejandro Teper¹³¹; Ronald P. Torres Gutiérrez²²¹; Juan
- 1226 Torres-Macho²⁶¹; Lilian Torres-Tobar³⁹; Jesús Troya²⁴³; Miguel Urioste¹⁹⁹; Juan
- 1227 Valencia-Ramos²⁶²; Agustín Valido^{21,263}; Juan Pablo Vargas Gallo^{264,265}; Belén
- 1228 Varón²⁶⁶; Romero H.T. Vasconcelos²⁶⁰; Tomas Vega²⁶⁷; Santiago Velasco-Quirce²⁶⁸;
- Julia Vidán Estévez¹¹; Miriam Vieitez-Santiago^{45,47}; Carlos Vilches²⁶⁹; Lavinia
- 1230 Villalobos¹¹; Felipe Villar²¹⁸; Judit Villar-Garcia^{270,271,272}; Cristina Villaverde^{26,27}; Pablo
- 1231 Villoslada-Blanco²¹⁴; Ana Virseda-Berdices⁶⁹; Valentina Vélez-Santamaría^{87,88};
- 1232 Virginia Víctor^{35,36}; Zuleima Yáñez²⁰; Antonio Zapatero-Gaviria²⁷³; Ruth Zarate²⁷⁴;
- 1233 Sandra Zazo²³⁶; Gabriela V. da Silva⁴¹; Raimundo de Andrés²⁷⁵; Jéssica N.G. de
- 1234 Araújo²⁵²; Carmen de Juan²⁰¹; Julianna Lys de Sousa Alves Neri²⁷⁶; Carmen de la
- Horra⁷⁹; Ana B. de la Hoz³³; Victor del Campo-Pérez²⁷⁷; Manoella do Monte
- 1236 Alves^{278,279}; Katiusse A. dos Santos⁸⁶; Yady Álvarez-Benítez^{19,20}; Felipe Álvarez-
- 1237 Navia^{81,58}; María Íñiguez²¹⁴; Miguel López de Heredia²⁷; Ingrid Mendes²⁷; Rocío
- 1238 Moreno²⁷; Esther Sande^{27,129,102}; Carlos Flores^{280,98,99,234}; José A. Riancho^{45,46,47,27};
- Augusto Rojas-Martinez⁸²; Pablo Lapunzina^{27,130,205}; Angel Carracedo^{27,129,102,128}
- 1240 Scourge Cohort Group's filiations
- 1241 ¹, Hospital Universitario Mostoles, Medicina Interna, Madrid, Spain
- 1242 ², Universidad Francisco de Vitoria, Madrid, Spain

- 1243 ³, Haemostasis and Thrombosis Unit, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
- 1244 Barcelona, Spain
- ⁴, Unit of Infectious Diseases, Hospital Universitario 12 de Octubre, Instituto de Investigación
- 1246 Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
- ⁵, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0002), Instituto de
- 1248 Salud Carlos III, Madrid, Spain
- 1249 ⁶, School of Medicine, Universidad Complutense, Madrid, Spain
- 1250 ⁷, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC),
- 1251 Instituto de Salud Carlos III, Madrid, Spain
- 1252 ⁸, Hospital General Santa Bárbara de Soria, Soria, Spain
- ⁹, Pediatric Neurology Unit, Department of Pediatrics, Navarra Health Service Hospital,
- 1254 Pamplona, Spain
- 1255 ¹⁰, Navarra Health Service, NavarraBioMed Research Group, Pamplona, Spain
- 1256 ¹¹, Complejo Asistencial Universitario de León, León, Spain
- 1257 ¹², Hospital Universitario San Pedro, Infectious Diseases Department, Logroño, Spain
- 1258 ¹³, Fundación Institut Guttmann, Institut Universitari de Neurorehabilitació adscrit a la UAB,
- 1259 Hospital de Neurorehabilitació, Barcelona, Spain
- 1260 ¹⁴, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
- 1261 ¹⁵, Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol, Barcelona,
- 1262 Spain
- 1263 ¹⁶, Hospital General de Occidente, Guadalajara, Mexico
- 1264 ¹⁷, Microbiology Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife,
- 1265 Spain
- 1266 ¹⁸. Hospital Universitario La Paz-IDIPAZ, Servicio de Neumología, Madrid, Spain
- 1267 ¹⁹, Camino Universitario Adelita de Char, Mired IPS, Barranquilla, Colombia
- 1268 ²⁰, Universidad Simón Bolívar, Facultad de Ciencias de la Salud, Barranquilla, Colombia
- 1269 ²¹, Hospital Universitario Virgen Macarena, Neumología, Seville, Spain
- 1270 ²², Departamento de Medicina, Universidad de Salamanca, Salamanca, Spain
- 1271 ²³, Centro de Investigación del Cáncer (IBMCC) Universidad de Salamanca CSIC, Salamanca,
- 1272 Spain
- 1273 ²⁴, Biomedical Research Institute of Salamanca (IBSAL) Salamanca, Spain
- 1274 ²⁵, Centre for Biomedical Network Research on Cancer (CIBERONC), Instituto de Salud Carlos
- 1275 III, Madrid, Spain
- 1276 ²⁶, Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez
- 1277 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1278 ²⁷, Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud
- 1279 Carlos III, Madrid, Spain
- 1280 ²⁸, Spanish National Cancer Research Centre, Human Genotyping-CEGEN Unit, Madrid, Spain
- 1281 ²⁹, Hospital das Forças Armadas, Brazil

- 1282 ³⁰, Exército Brasileiro, Brazil
- 1283 ³¹, Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health,
- 1284 Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 1285 ³², Clinical Pharmacology Service, Hospital de la Santa Creu i Sant Pau, IIB Sant Pau,
- 1286 Barcelona, Spain
- 1287 ³³, Biocruces Bizkai HRI, Barakaldo, Bizkaia, Spain
- 1288 ³⁴, Cruces University Hospital, Osakidetza, Barakaldo, Bizkaia, Spain
- 1289 ³⁵, Hospital Infanta Elena, Valdemoro, Madrid, Spain
- 1290 ³⁶, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital -
- 1291 Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1292 ³⁷, Centre for Biomedical Network Research on Mental Health (CIBERSAM), Instituto de Salud
- 1293 Carlos III, Madrid, Spain
- 1294 ³⁸, Fundación Hospital Infantil Universitario de San José, Bogotá, Colombia
- 1295 ³⁹, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia
- 1296 ⁴⁰, Universidade Federal do Rio Grande do Norte, Programa de Pós-graduação em Ciências da
- 1297 Saúde, Natal, Brazil
- 1298 ⁴¹, Universidade Federal do Rio Grande do Norte, Departamento de Medicina Clínica, Natal,
- 1299 Brazil
- 1300 ⁴², Departamento de Genética e Morfologia, Instituto de Ciências Biológicas, Universidade de
- 1301 Brasília, Brasilia, Brazil
- 1302 ⁴³, Colégio Marista de Brasilia, Brazil
- 1303 ⁴⁴, Associação Brasileira de Educação e Cultura, Brazil
- 1304 ⁴⁵, IDIVAL, Santander, Spain
- 1305 ⁴⁶, Universidad de Cantabria, Santander, Spain
- 1306 ⁴⁷, Hospital U M Valdecilla, Santander, Spain
- 1307 ⁴⁸, Hospital Universitario La Paz-IDIPAZ, Servicio de Medicina Interna, Madrid, Spain
- 1308 ⁴⁹, Fundació Docència I Recerca Mutua Terrassa, Barcelona, Spain
- 1309 ⁵⁰, Spanish National Cancer Research Center, CNIO Biobank, Madrid, Spain
- 1310 ⁵¹, Fundación Santa Fe de Bogota, Departamento Patologia y Laboratorios, Bogotá, Colombia
- 1311 ⁵², Hospital General de Occidente, Zapopan, Jalisco, Mexico
- 1312 ⁵³, Centro Universitario de Tonalá, Universidad de Guadalajara, Tonalá, Jalisco, Mexico
- 1313 ⁵⁴, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara, Tonalá,
- 1314 Jalisco, Mexico
- 1315 ⁵⁵, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), Murcia, Spain
- 1316 ⁵⁶, Universidad Católica San Antonio de Murcia (UCAM), Murcia, Spain
- 1317 ⁵⁷, Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna-Unidad de
- 1318 Enfermedades Infecciosas, Salamanca, Spain
- 1319 ⁵⁸, Universidad de Salamanca, Salamanca, Spain

- 1320 ⁵⁹, Hospital Universitario de Fuenlabrada, Department of Internal Medicine, Madrid, Spain
- 1321 ⁶⁰, Escola Tecnica de Saúde, Laboratorio de Vigilancia Molecular Aplicada, Pará, Brazil
- 1322 ⁶¹, Federal University of Pernambuco, Genetics Postgraduate Program, Recife, PE, Brazil
- 1323 ⁶², Hospital Universitario Infanta Leonor, Servicio de Alergia, Madrid, Spain
- 1324 ⁶³, Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Aranjuez, Spain
- 1325 ⁶⁴, Hospital Universitario Mutua Terrassa, Barcelona, Spain
- 1326 ⁶⁵, Hospital Universitario La Paz-IDIPAZ, Servicio de Farmacología, Madrid, Spain
- 1327 ⁶⁶, Alcaldía de Barranquilla, Secretaría de Salud, Barranquilla, Colombia
- 1328 ⁶⁷, Instituto de Investigación Sanitaria de Santiago (IDIS), Xenética Cardiovascular, Santiago de
- 1329 Compostela, Spain
- 1330 ⁶⁸, Centre for Biomedical Network Research on Cardiovascular Diseases (CIBERCV), Instituto
- 1331 de Salud Carlos III, Madrid, Spain
- 1332 ⁶⁹, Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología (CNM), Instituto
- de Salud Carlos III (ISCIII), Madrid, Spain
- 1334 ⁷⁰, Cardiovascular Genetics Center, Institut d'Investigació Biomèdica Girona (IDIBGI), Girona,
- 1335 Spain
- 1336 ⁷¹, Medical Science Department, School of Medicine, University of Girona, Girona, Spain
- 1337 ⁷², Hospital Josep Trueta, Cardiology Service, Girona, Spain
- 1338 ⁷³, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 1339 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 1340 ⁷⁴, Division of Infectious Diseases, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1341 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1342 ⁷⁵, Intensive Care Unit, Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran
- 1343 Canaria, Spain
- 1344 ⁷⁶, Hospital Universitario Mutua Terrassa, Terrassa, Spain
- 1345 ⁷⁷, Departamento de Medicina, Hospital Universitario Virgen del Rocío, Universidad de Sevilla,
- 1346 Seville, Spain
- 1347 ⁷⁸, Centre for Biomedical Network Research on Epidemiology and Public Health (CIBERESP),
- 1348 Instituto de Salud Carlos III, Madrid, Spain
- 1349 ⁷⁹, Institute of Biomedicine of Seville (IBiS), Consejo Superior de Investigaciones Científicas
- 1350 (CSIC)- University of Seville- Virgen del Rocio University Hospital, Seville, Spain
- 1351 ⁸⁰, Universidad de los Andes, Facultad de Ciencias, Bogotá, Colombia
- 1352 81. Hospital Universitario de Salamanca-IBSAL, Servicio de Medicina Interna, Salamanca,
- 1353 Spain
- 1354 ⁸², Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud and Hospital San
- 1355 Jose TecSalud, Monterrey, Mexico
- 1356 ⁸³, University of Fortaleza (UNIFOR), Department of Nutrition. Fortaleza, Brazil
- 1357 ⁸⁴, Departamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto,
- 1358 Universidade de São Paulo, Brazil

- 1359 ⁸⁵, Andalusian Public Health System Biobank, Granada, Spain
- 1360 ⁸⁶, Universidade Federal do Rio Grande do Norte, Programa de Pós-Graduação em Ciências
- 1361 Farmacêuticas, Natal, Brazil
- 1362 ⁸⁷, Neuromuscular Unit, Neurology Department, Hospital Universitari de Bellvitge,
- 1363 L'Hospitalet de Llobregat (Barcelona), Spain
- 1364 ⁸⁸, Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory,
- 1365 L'Hospitalet de Llobregat, Spain
- 1366 ⁸⁹, Centre for Biomedical Network Research on Diabetes and Metabolic Associated Diseases
- 1367 (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain
- 1368 ⁹⁰, University of Pais Vasco, UPV/EHU, Bizkaia, Spain
- 1369 ⁹¹, Oncology and Genetics Unit, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de
- 1370 Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
- 1371 ⁹², Hospital Universitario La Paz, Hospital Carlos III, Madrid, Spain
- 1372 ⁹³, Hospital de San José, Sociedad de Cirugía de Bogota, Bogotá, Colombia
- 1373 ⁹⁴, Hospital Universitario Río Hortega, Valladolid, Spain
- 1374 ⁹⁵, Servicio de Medicina intensiva, Complejo Hospitalario Universitario de A Coruña
- 1375 (CHUAC), Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 1376 ⁹⁶, Valencia University, Preventive Medicine Department, Valencia, Spain
- 1377 ⁹⁷, Centre for Biomedical Network Research on Physiopatology of Obesity and Nutrition
- 1378 (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain
- 1379 ⁹⁸, Research Unit, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, Spain
- 1380 ⁹⁹, Centre for Biomedical Network Research on Respiratory Diseases (CIBERES), Instituto de
- 1381 Salud Carlos III, Madrid, Spain
- 1382 ¹⁰⁰, Otto von Guericke University, Departament of Microgravity and Translational Regenerative
- 1383 Medicine, Magdeburg, Germany
- 1384 ¹⁰¹, Maternidade Escola Janário Cicco, Natal, Brazil
- 1385 ¹⁰², Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas
- 1386 (CIMUS), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
- 1387 ¹⁰³, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón
- 1388 (IiSGM), Madrid, Spain
- 1389 ¹⁰⁴, Programa de Pós Graduação em Ciências da Saúde, Faculdade de Medicina, Universidade
- 1390 de Brasília, Brasilia, Brazil
- 1391 ¹⁰⁵, Fundació Docència I Recerca Mutua Terrassa, Terrassa, Spain
- 1392 ¹⁰⁶, Hospital Universitario Mostoles, Unidad de Genética, Madrid, Spain
- 1393 ¹⁰⁷, Instituto Aragonés de Ciencias de la Salud (IACS), Zaragoza, Spain
- 1394 ¹⁰⁸, Instituto Investigación Sanitaria Aragón (IIS-Aragon), Zaragoza, Spain
- 1395 ¹⁰⁹, Department of Preventive Medicine and Public Health, School of Medicine, Universidad
- 1396 Autónoma de Madrid, Madrid, Spain
- 1397 ¹¹⁰, IdiPaz (Instituto de Investigación Sanitaria Hospital Universitario La Paz), Madrid, Spain

- 1398 ¹¹¹, Hospital Universitario Virgen del Rocío, Servicio de Medicina Interna, Seville, Spain
- 1399 ¹¹², Unidad Diagnóstico Molecular. Fundación Rioja Salud, La Rioja, Spain
- 1400 ¹¹³, Hospital Universitario Quironsalud Madrid, Madrid, Spain
- 1401 ¹¹⁴, Hospital Universitario de Salamanca-IBSAL, Servicio de Cardiología, Salamanca, Spain
- 1402 ¹¹⁵, Hospital Universitario Puerta de Hierro, Servicio de Medicina Interna, Majadahonda, Spain
- 1403 ¹¹⁶, Biocruces Bizkaia Health Research Institute, Galdakao University Hospital, Osakidetza,
- 1404 Bizkaia, Spain
- 1405 ¹¹⁷, Instituto Regional de Investigación en Salud-Universidad Nacional de Caaguazú, Caaguazú,
- 1406 Paraguay
- 1407 ¹¹⁸, Universidade Federal do Pará, Núcleo de Pesquisas em Oncologia, Belém, Pará, Brazil
- 1408 ¹¹⁹, Hospital Ophir Loyola, Departamento de Ensino e Pesquisa, Belém, Pará, Brazil
- 1409 ¹²⁰, Universidad Nacional de Asunción, Facultad de Politécnica, Paraguay
- 1410 ¹²¹, Fundación Asilo San Jose, Santander, Spain
- 1411 ¹²², Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario
- 1412 Puerta de Hierro, Instituto de Investigación Sanitaria Puerta de Hierro Segovia de Arana,
- 1413 Madrid, Spain
- 1414 ¹²³, Urgencias Hospitalarias, Complejo Hospitalario Universitario de A Coruña (CHUAC),
- 1415 Sistema Galego de Saúde (SERGAS), A Coruña, Spain
- 1416 124, Grupo de Investigación en Interacciones Gen-Ambiente y Salud (GIIGAS) Instituto de
- 1417 Biomedicina (IBIOMED), Universidad de León, León, Spain
- 1418 ¹²⁵, Hospital Universitario Niño Jesús, Pediatrics Department, Madrid, Spain
- 1419 ¹²⁶, Unitat de Malalties Infeccioses i Importades, Servei de Pediatría, Infectious and Imported
- 1420 Diseases, Pediatric Unit, Hospital Universitari Sant Joan de Deú, Barcelona, Spain
- 1421 ¹²⁷, Microbiology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1422 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1423 ¹²⁸, Fundación Pública Galega de Medicina Xenómica, Sistema Galego de Saúde (SERGAS)
- 1424 Santiago de Compostela, Spain
- 1425 ¹²⁹, Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Spain
- 1426 ¹³⁰, Instituto de Genética Médica y Molecular (INGEMM), Hospital Universitario La Paz-
- 1427 IDIPAZ, Madrid, Spain
- 1428 ¹³¹, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina
- 1429 ¹³², Centre for Biomedical Network Research on Rare Diseases (CIBERER), Instituto de Salud
- 1430 Carlos III, Madrid, Spain Universidad Francisco de Vitoria, Madrid, Spain
- 1431 ¹³³, Hospital Infanta Elena, Servicio de Medicina Intensiva, Valdemoro, Madrid, Spain
- 1432 ¹³⁴, University of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), Salamanca,
- 1433 Spain
- 1434 ¹³⁵, Department of Immunology, IRYCIS, Hospital Universitario Ramón y Cajal, Madrid, Spain
- 1435 ¹³⁶, Osakidetza, Cruces University Hospital, Bizkaia, Spain

- 1436 ¹³⁷, Instituto Mexicano del Seguro Social, IMSS. Centro Médico Nacional La Raza. Hospital de
- 1437 Infectología. Mexico City, Mexico.
- 1438 ¹³⁸, Hospital Universitario de Getafe, Servicio de Genética, Madrid, Spain
- 1439 ¹³⁹, Ministerio de Salud Ciudad de Buenos Aires, Buenos Aires, Argentina
- 1440 ¹⁴⁰, Hospital Clinico Universitario de Valladolid, Unidad de Apoyo a la Investigación,
- 1441 Valladolid, Spain
- 1442 ¹⁴¹, Universidad de Valladolid, Departamento de Cirugía, Valladolid, Spain
- 1443 ¹⁴², Secretaria Municipal de Saude de Apodi, Natal, Brazil
- 1444 ¹⁴³, Sección Genética Médica Servicio de Pediatría, Hospital Clínico Universitario Virgen de la
- 1445 Arrixaca, Servicio Murciano de Salud, Murcia, Spain
- 1446 ¹⁴⁴, Departamento Cirugía, Pediatría, Obstetricia y Ginecología, Facultad de Medicina,
- 1447 Universidad de Murcia (UMU), Murcia, Spain
- 1448 ¹⁴⁵, Hospital Universitario Centro Dermatológico Federico Lleras Acosta, Bogotá, Colombia
- 1449 ¹⁴⁶, Hospital Universitario Virgen de las Nieves, Servicio de Análisis Clínicos e Inmunología,
- 1450 Granada, Spain
- 1451 ¹⁴⁷, Pneumology Department, Hospital General Universitario Gregorio Marañón (iiSGM),
- 1452 Madrid, Spain
- 1453 ¹⁴⁸, Intermediate Respiratory Care Unit, Department of Pneumology, Instituto de Investigación
- 1454 Sanitaria-Fundación Jiménez Díaz University Hospital Universidad Autónoma de Madrid (IIS-
- 1455 FJD, UAM), Madrid, Spain
- 1456 ¹⁴⁸, Clinica Comfamiliar Risaralda, Pereira, Colombia
- 1457 ¹⁵⁰, Centro Universitario de Tonalá, Universidad de Guadalajara, Guadalajara, Mexico
- 1458 ¹⁵¹, Centro de Investigación Multidisciplinario en Salud, Universidad de Guadalajara,
- 1459 Guadalajara, Mexico
- 1460 ¹⁵², Unidad de Cuidados, Intensivos Hospital Clínico Universitario de Santiago (CHUS),
- 1461 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 1462 ¹⁵³, IIS La Fe, Plataforma de Farmacogenética, Valencia, Spain
- 1463 ¹⁵⁴, Universidad de Valencia, Departamento de Farmacología, Valencia, Spain
- 1464 ¹⁵⁵, Data Analysis Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1465 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1466 ¹⁵⁶, Hospital del Mar, Infectious Diseases Service, Barcelona, Spain
- 1467 ¹⁵⁷, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain
- 1468 ¹⁵⁸, CEXS-Universitat Pompeu Fabra, Spanish Network for Research in Infectious Diseases
- 1469 (REIPI), Barcelona, Spain
- 1470 ¹⁵⁹, Biocruces Bizkaia Health Research Institute, Basurto University Hospital, Osakidetza,
- 1471 Bizkaia, Spain
- 1472 ¹⁶⁰. Sabin Medicina Diagnóstica, Brazil
- 1473 ¹⁶¹, Opthalmology Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1474 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1475 ¹⁶², Hospital Sant Joan de Deu, Pediatric Critical Care Unit, Barcelona, Spain

- 1476 ¹⁶³, Paediatric Intensive Care Unit, Agrupación Hospitalaria Clínic-Sant Joan de Déu,
- 1477 Esplugues de Llobregat, Barcelona, Spain
- 1478 ¹⁶⁴, Hospital Universitario 12 de Octubre, Department of Immunology, Madrid, Spain
- 1479 ¹⁶⁵, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Transplant
- 1480 Immunology and Immunodeficiencies Group, Madrid, Spain
- 1481 ¹⁶⁶, SIGEN Alianza Universidad de los Andes Fundación Santa Fe de Bogotá, Bogotá,
- 1482 Colombia
- 1483 ¹⁶⁷, Hospital General de Segovia, Medicina Intensiva, Segovia, Spain
- 1484 ¹⁶⁸, Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil
- 1485 ¹⁶⁹, Clinical Trials Unit, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University
- 1486 Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1487 ¹⁷⁰, IMDEA-Food Institute, CEI UAM+CSIC, Madrid, Spain
- 1488 ¹⁷¹, Intensive Care Unit, Hospital Universitario de Canarias, La Laguna, Spain
- 1489 ¹⁷², Dirección General de Salud Pública, Consejería de Sanidad, Junta de Castilla y León,
- 1490 Valladolid, Spain
- 1491 ¹⁷³, Universidade Federal do Rio Grande do Norte, Departamento de Analises Clinicas e
- 1492 Toxicologicas, Natal, Brazil
- 1493 ¹⁷⁴, Hospital Universitario La Paz-IDIPAZ, Servicio de Inmunología, Madrid, Spain
- 1494 ¹⁷⁵, La Paz Institute for Health Research (IdiPAZ), Lymphocyte Pathophysiology in
- 1495 Immunodeficiencies Group, Madrid, Spain
- 1496 ¹⁷⁶, Hospital Universitario Virgen de las Nieves, Servicio de Enfermedades Infecciosas,
- 1497 Granada, Spain
- 1498 ¹⁷⁷, Instituto de Investigación Biosanitaria de Granada (ibs GRANADA), Granada, Spain
- 1499 ¹⁷⁸, Universidad de Granada, Departamento de Medicina, Granada, Spain
- 1500 ¹⁷⁹, Faculdade de Medicina, Universidade de Brasília, Brasilia, Brazil
- 1501 ¹⁸⁰, Fundación Jiménez Díaz, Epidemiology, Madrid, Spain
- 1502 ¹⁸¹, Universidad Autónoma de Madrid, Department of Medicine, Madrid, Spain
- 1503 ¹⁸², Universidad de Valladolid, Departamento de Medicina, Valladolid, Spain
- 1504 ¹⁸³, Hospital Universitario Infanta Leonor, Servicio de Medicina Intensiva, Madrid, Spain
- 1505 ¹⁸⁴, Unidad de Genética y Genómica Islas Baleares, Islas Baleares, Spain
- 1506 ¹⁸⁵, Hospital Universitario Son Espases, Unidad de Diagnóstico Molecular y Genética Clínica,
- 1507 Islas Baleares, Spain
- 1508 ¹⁸⁶, Genomics of Complex Diseases Unit, Research Institute of Hospital de la Santa Creu i Sant
- 1509 Pau, IIB Sant Pau, Barcelona, Spain
- 1510 ¹⁸⁷, Intensive Care Unit, Hospital Universitario N. S. de Candelaria, Santa Cruz de Tenerife,
- 1511 Spain
- 1512 ¹⁸⁸, Preventive Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez
- 1513 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1514 ¹⁸⁹, Servicio de Medicina Interna, Sanatorio Franchin, Buenos Aires, Argentina

- 1515 ¹⁹⁰, Hospital Universitario del Tajo, Servicio de Medicina Intensiva, Toledo, Spain
- 1516 ¹⁹¹, Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasilia, Brazil
- 1517 ¹⁹², Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasilia,
- 1518 Brazil
- 1519 ¹⁹³, Hospital El Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia
- 1520 Regional de Salud (SACYL), Ponferrada, Spain
- 1521 ¹⁹⁴, Grupo INVESTEN, Instituto de Salud Carlos III, Madrid, Spain
- 1522 ¹⁹⁵, Unidad de Cuidados Intensivos, Complejo Universitario de A Coruña (CHUAC), Sistema
- 1523 Galego de Saúde (SERGAS), A Coruña, Spain
- 1524 ¹⁹⁶ Programa de Pós-Graduação em Genética da Faculdade de Medicina de Ribeirão Preto
- 1525 Programa de Pós-Graduação em Química da Faculdade de Filosofia, Ciências e Letras de
- 1526 Ribeirão Preto
- 1527 ¹⁹⁸, Hospital El Bierzo, Unidad Cuidados Intensivos, León, Spain
- 1528 ¹⁹⁹, Spanish National Cancer Research Centre, Familial Cancer Clinical Unit, Madrid, Spain
- 1529 ²⁰⁰, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital Clínico San Carlos
- 1530 (HCSC), Madrid, Spain
- 1531 ²⁰¹, Hospital Universitario Severo Ochoa, Servicio de Medicina Interna, Madrid, Spain
- 1532 ²⁰², Universidad de Sevilla, Departamento de Enfermería, Seville, Spain
- 1533 ²⁰³, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain
- 1534 ²⁰⁴, Hospital Universitario La Paz-IDIPAZ, Servicio de Pediatría, Madrid, Spain
- 1535 ²⁰⁵, ERN-ITHACA-European Reference Network
- 1536 ²⁰⁶, Unidad de Genética y Genómica Islas Baleares, Unidad de Diagnóstico Molecular y
- 1537 Genética Clínica, Hospital Universitario Son Espases, Islas Baleares, Spain
- 1538 ²⁰⁷, Instituto de Investigación Sanitaria Islas Baleares (IdISBa), Islas Baleares, Spain
- 1539 ²⁰⁸, Programa de Pós-Graduação em Biologia Animal, Universidade de Brasília, Brasília, Brazil
- 1540 ²⁰⁹, Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília,
- 1541 Brazil
- 1542 ²¹⁰, Programa de Pós-Graduação Profissional em Ensino de Biologia, Universidade de Brasília,
- 1543 Brasília, Brazil
- 1544 ²¹¹, Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, Brazil
- 1545 ²¹², Anatomía Patológica, Instituto de Investigación Sanitaria San Carlos (IdISSC), Hospital
- 1546 Clínico San Carlos (HCSC), Madrid, Spain
- 1547 ²¹³, Tecnológico de Monterrey, Monterrey, Mexico
- 1548 ²¹⁴, Infectious Diseases, Microbiota and Metabolism Unit, CSIC Associated Unit, Center for
- 1549 Biomedical Research of La Rioja (CIBIR), Logroño, Spain
- 1550 ²¹⁵, Centro de Investigación en Anomalías Congénitas y Enfermedades Raras (CIACER),
- 1551 Universidad Icesi
- 1552 ²¹⁶, Departamento de Genetica, Fundación Valle del Lili
- 1553 ²¹⁷, Universidad Complutense de Madrid, Department of Immunology, Ophthalmology and
- 1554 ENT, Madrid, Spain

- 1555 ²¹⁸, Department of Neumology, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1556 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1557 ²¹⁹, Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 1558 ²²⁰, Inditex, A Coruña, Spain
- 1559 ²²¹, Osakidetza, Cruces University Hospital, Barakaldo, Bizkaia, Spain
- 1560 ²²², GENYCA, Madrid, Spain
- 1561 ²²³, Neuromuscular Diseases Unit, Department of Neurology, Hospital de la Santa Creu i Sant
- 1562 Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
- 1563 ²²⁴, Instituto Mexicano del Seguro Social (IMSS), Centro Médico Nacional Siglo XXI, Unidad
- de Investigación Médica en Enfermedades Infecciosas y Parasitarias, Mexico City, Mexico
- 1565 ²²⁵, Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain
- 1566 ²²⁶, Intensive Care Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1567 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1568 ²²⁷, Hospital Universitario Príncipe de Asturias, Servicio de Microbiología Clínica, Madrid,
- 1569 Spain
- 1570 ²²⁸, Universidad de Alcalá de Henares, Departamento de Biomedicina y Biotecnología, Facultad
- de Medicina y Ciencias de la Salud, Madrid, Spain
- 1572 ²²⁹, Drug Research Centre, Institut d'Investigació Biomèdica Sant Pau, IIB-Sant Pau, Barcelona,
- 1573 Spain
- 1574 ²³⁰, Departamento de Genetica, Clinica imbanaco
- 1575 ²³¹, Unidad de Cuidados Intensivos, Hospital Clínico Universitario de Santiago (CHUS),
- 1576 Sistema Galego de Saúde (SERGAS), Santiago de Compostela, Spain
- 1577 ²³², Universidade de Brasília, Brasilia, Brazil
- 1578 ²³³, Department of Immunology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas
- 1579 de Gran Canaria, Spain
- 1580 ²³⁴, Department of Clinical Sciences, University Fernando Pessoa Canarias, Las Palmas de Gran
- 1581 Canaria, Spain
- 1582 ²³⁵, University Hospital Germans Trias i Pujol, Pediatrics Department, Badalona, Spain
- 1583 ²³⁶, Department of Pathology, Biobank, Instituto de Investigación Sanitaria-Fundación Jiménez
- 1584 Díaz University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1585 ²³⁷, Hospital Universitario Virgen de las Nieves, Servicio de Medicina Interna, Granada, Spain
- 1586 ²³⁸, Fundación Universitaria de Ciencias de la Salud, Grupo de Ciencias Básicas en Salud
- 1587 (CBS), Bogotá, Colombia
- 1588 ²³⁹, Sociedad de Cirugía de Bogotá, Hospital de San José, Bogotá, Colombia
- 1589 ²⁴⁰, Universidad de Granada, Departamento Bioquímica, Biología Molecular e Inmunología III,
- 1590 Granada, Spain
- 1591 ²⁴¹, Hospital Infanta Elena, Allergy Unit, Valdemoro, Madrid, Spain
- 1592 ²⁴², Faculty of Medicine, Universidad Francisco de Vitoria, Madrid, Spain
- 1593 ²⁴³, Hospital Universitario Infanta Leonor, Madrid, Spain

- 1594 ²⁴⁴, Complutense University of Madrid, Madrid, Spain
- 1595 ²⁴⁵, Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain
- 1596 ²⁴⁶ Colégio Militar de Brasília
- 1597 ²⁴⁷, The John Walton Muscular Dystrophy Research Centre, Newcastle University and
- 1598 Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
- 1599 ²⁴⁸, Neuromuscular Unit, Neuropediatrics Department, Institut de Recerca Sant Joan de Déu,
- 1600 Hospital Sant Joan de Déu, Spain
- 1601 ²⁴⁹, Fundació Docència i Recerca Mutua Terrassa, Terrassa, Spain
- 1602 ²⁵⁰, Casa de Saúde São Lucas, Natal, Brazil
- 1603 ²⁵¹, Hospital Rio Grande, Rio Grande do Norte, Natal, Brazil
- 1604 ²⁵², Universidade Federal do Rio Grande do Norte, Pós-graduação em Biotecnologia Rede de
- 1605 Biotecnologia do Nordeste (Renorbio), Natal, Brazil
- 1606 ²⁵³, Intensive Care Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran
- 1607 Canaria, Spain
- 1608 ²⁵⁴, Universidad Fernando Pessoa Canarias, Las Palmas de Gran Canaria, Spain
- 1609 ²⁵⁵, Biobank, Puerta de Hierro-Segovia de Arana Health Research Institute, Madrid, Spain
- 1610 ²⁵⁶, Universidad Rey Juan Carlos, Madrid, Spain
- 1611 ²⁵⁷, Reumathology Service, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz
- 1612 University Hospital Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
- 1613 ²⁵⁸, Hospital Clinico Universitario de Valladolid, Servicio de Anestesiologia y Reanimación,
- 1614 Valladolid, Spain
- 1615 ²⁵⁹, Hospital Clinico Universitario de Valladolid, Servicio de Hematologia y Hemoterapia,
- 1616 Valladolid, Spain
- 1617 ²⁶⁰. Hospital Universitario Lauro Wanderley, Brazil
- 1618 ²⁶¹, Hospital Universitario Infanta Leonor, Servicio de Medicina Interna, Madrid, Spain
- 1619 ²⁶², University Hospital of Burgos, Burgos, Spain
- 1620 ²⁶³. Universidad de Sevilla, Seville, Spain
- 1621 ²⁶⁴, Fundación Santa Fe de Bogota, Instituto de servicios medicos de Emergencia y trauma,
- 1622 Bogotá, Colombia
- 1623 ²⁶⁵. Universidad de los Andes, Bogotá, Colombia
- 1624 ²⁶⁶, Quironprevención, A Coruña, Spain
- 1625 ²⁶⁷, Junta de Castilla y León, Consejería de Sanidad, Valladolid, Spain
- 1626 ²⁶⁸, Gerencia Atención Primaria de Burgos, Burgos, Spain
- 1627 ²⁶⁹, Immunogenetics-Histocompatibility group, Servicio de Inmunología, Instituto de
- 1628 Investigación Sanitaria Puerta de Hierro Segovia de Arana, Madrid, Spain
- 1629 ²⁷⁰, Hospital del Mar, Department of Infectious Diseases, Barcelona, Spain
- 1630 ²⁷¹, IMIM (Hospital del Mar Medical Research Institute, Institut Hospital del Mar
- d'Investigacions Mediques), Barcelona, Spain
- 1632 ²⁷², Universitat Autònoma de Barcelona, Department of Medicine, Spain

²⁷³, Consejería de Sanidad, Comunidad de Madrid, Madrid, Spain
²⁷⁴, Centro para el Desarrollo de la Investigación Científica, Asunción, Paraguay
²⁷⁵, Internal Medicine Department, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital - Universidad Autónoma de Madrid (IIS-FJD, UAM), Madrid, Spain
²⁷⁶, Universidade Federal do Rio Grande do Norte, Programa de Pós Graduação em Nutrição, Natal, Brazil
²⁷⁷, Preventive Medicine Department, Instituto de Investigacion Sanitaria Galicia Sur, Xerencia de Xestion Integrada de Vigo-Servizo Galego de Saúde, Vigo, Spain
²⁷⁸, Universidade Federal do Rio Grande do Norte, Departamento de Infectologia, Natal, Brazil
²⁷⁹, Hospital de Doenças Infecciosas Giselda Trigueiro, Rio Grande do Norte, Natal, Brazil
²⁸⁰, Genomics Division, Instituto Tecnológico y de Energías Renovables, Santa Cruz de Tenerife, Spain